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Abstract
Influenza virus (IV) circulating worldwide, are highly contagious and can cause acute
to severe respiratory disease. Annually, around 500 million individual get infected with
influenza, which causes about 500,000 deaths worldwide, including 5000-8000 deaths in
Germany. The biological basis for the increased severity of some IVs remains unclear.
Recently, it is shown that variability of the amino acid in the 222-position of Hemagglu-
tinin (HA-222) allows evolution of quasispecies in the host organism and is associated
with strong inflammation as an important hallmarks of severe infection with pandemic
H1N1 influenza A virus of 2009 (A(H1N1)pdm09) (Seidel et al., 2014). modelling in-
fluenza kinetics plays an integral role in understanding the differences and pathogenicity
of influenza viruses of different virulence. Moreover, investigating the molecular mecha-
nisms of severe A(H1N1)pdm09 is of great importance in controlling the complications
and reducing the pulmonary damage.
Together, this emphasises the need to develop a new small-scale mathematical model
focussed with only a few state variables describing influenza A virus (IAV) kinetics of
different strains. Consequently, categorizing them into mild and severe IAV strains,
based on a handful of parameters. For the first time, we did the modelling for dynamics
of four different IAV strains and the established model allows quantifying the infection
process by using a few interpretable parameters (Manchanda et al 2014). The modelling
results also revealed that the late pro-inflammatory response plays some adverse role
on the disease condition. Most importantly, the pro-inflammatory response is specific
for the virus strain thus therapeutic profile should be design specifically for the virus
strains.
After finding the severe A(H1N1)pdm09 strain,A/Jena/5258/2009, we performed a com-
prehensive analysis of whole genome expression changes of the lung of BALB/c-mice
infected with mouse-passaged isolate A/Jena/5258/2009 (mpJena/5258). Surprisingly,
most of the genes differentially expressed during mpJena/5258 infection is associates
with biphasic gene expression profile. Finally, using a reverse engineering strategy to
construct a regulatory network which give us more insight into key interactions lead-
ing to severe pathogenesis. The inferred gene regulatory network of influenza infection
shows a positive feed-back loop. The gene Ifng coding for interferon gamma is involve in
the positive feedback mechanism is associates with the IAV infection, which correlates
with evolution of HA-222D/G quasispecies found by Seidel et al 2014., and leads to
overwhelming immune response.
Our results show insights into the host factors involved in the severe A(H1N1)pdm09
and show a significant correlation of expression profiles of the genes involved in positive
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feedback loop (Ifng, Stat1 and Tlr3) with the clinical symptoms score. However, fur-
ther experimental investigation with gene expression profiling of the host will need to
understand differences in gene expression in mild and severe influenza. These findings
play a crucial role in the optimizing the therapeutic profile of drug administration and
shall be designed specifically for the virus strain.
Zusammenfassung
Influenzaviren zirkulieren weltweit, sind sehr ansteckend und ko¨nnen schwere akute
Erkrankungen der Atemwege verursachen. Ja¨hrlich werden weltweit rund 500 Mil-
lionen Personen mit Influenzaviren infiziert, mit etwa 500.000 Todesfa¨llen, darunter
5.000 bis 8.000 in Deutschland. Die biologische Grundlage fu¨r die Schwere einiger
Influenzavirus-Erkrankungen bleibt unklar. Unla¨ngst wurde gezeigt, dass die Vari-
abilita¨t der Aminosa¨ure im Ha¨magglutinin in Position 222 (HA-222) die Evolution von
Quasi-Spezies im Wirtsorganismus ermo¨glicht und mit starken Entzu¨ndungserscheinungen
als wichtige Kennzeichen einer schweren Infektion mit pandemischen H1N1 Influenza-
A-Viren von 2009 (A(H1N1)pdm09) assoziiert ist (Seidel et al., 2014).
Die Modellierung der Influenza-Kinetik liefert einen wichtigen Beitrag zum Versta¨ndnis
der Unterschiede und Pathogenita¨tsmechanismen von Influenzaviren unterschiedlicher
Virulenz. Daru¨ber hinaus ist die Untersuchung von molekularen Mechanismen der schw-
eren A(H1N1)pdm09-Infektion sehr wichtig fu¨r die Intervention bei Komplikationen und
zur Verringerung der Lungenscha¨den.
Dies unterstreicht die Notwendigkeit, ein neues fokussiertes mathematisches Modell mit
nur wenigen Zustandsgro¨ßen zu entwickeln, das den Verlauf der Infektionen mit ver-
schiedenen Influenza-A-Virus-Sta¨mmen im Wirt beschreibt und anhand weniger Param-
eter kategorisiert in milde und schwere Infektionen. Die Ergebnisse der Modellierung
zeigten, dass spa¨te pro-inflammatorische Reaktionen eine scha¨dliche Wirkung auf den
Krankheitszustand haben. Wichtig ist, dass die pro-inflammatorische Antwort spezifisch
fu¨r den Virusstamm ist, weshalb das therapeutische Profil individuell fu¨r den jeweiligen
Virusstamm gestaltet werden sollte.
Fu¨r den in BALB/c-Ma¨usen hoch-virulenten A(H1N1)pdm09-Stamm (A/Jena/5258/2009)
wurde eine detaillierte Analyse durchgefu¨hrt, indem die genomweite A¨nderung der Gen-
expression in der Lunge der infizierten Ma¨use untersucht wurde, die mit dem Maus-
passagierten Isolat A/Jena/5258/2009 (mpJena/5258) infiziert wurden. Schließlich wurde
mit einem Reverse-Engineering-Ansatz ein regulatorisches Netzwerk konstruiert, das
einen Einblick in die wichtigsten genregulatorischen Interaktionen unter den Bedingun-
gen der schweren mpJena/5258-Infektion erlaubt.
U¨berraschenderweise – und in dieser Arbeit erstmalig – konnte gezeigt werden, dass
die meisten differenziell exprimierten Gene Expressionsprofile u¨ber den Verlauf der
mpJena/5258“-IAV-Infektion haben, die zweigipflig sind. Das genregulatorische Netzw-
erkmodell zeigt eine positive Ru¨ckkopplungsschleife. Im rekonstruierten mathematischen
Netzwerkmodell sind die Expressionsprofile der Gene, die in die Ru¨ckkopplungsschleife
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eingebunden sind, mit der Entwicklung der HA-222D/G-Quasispezies des mpJena/5258
verbunden (Seidel et al., 2014). Es wurde eine signifikante Korrelation der Expression-
sprofile der zur Ru¨ckkopplungsschleife geho¨renden Gene IFNg, STAT1 und Tlr3 mit den
klinischen Symptomen gefunden.
Die Ergebnisse der Modellierung geben Einblicke in die wirtsseitigen Faktoren, die fu¨r
die schwere A(H1N1)pdm09-Infektion charakteristisch und hypothetisch auch verant-
wortlich sind. Es sind jedoch weitere experimentelle Untersuchung mit Genexpressions-
analysen des Wirtes erforderlich, um Unterschiede in der Genexpression bei einer milden
und und schweren Influenza zu verstehen. Diese Erkenntnisse ko¨nnten eine wichtige
Rolle fu¨r die Optimierung der antiviralen Therapie mit einem IAV-Stamm-spezifischen
Arzneimittel spielen.
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Chapter 1
Introduction
1.1 Influenza Virus
Influenza viruses (IV) circulating worldwide are highly contagious and can cause acute
to severe respiratory disease. Influenza viruses are remarkable in nature because of their
high mutability [1, 2] and high frequency of genetic reassortment and resulting antigenic
variations in the surface glycoproteins, Neuraminidase and Hemagglutinin. Annually
around 500 million individuals are infected by influenza virus, which cause about 500,000
deaths [3, 4] worldwide, including 5000-8000 deaths in Germany [5]. Influenza type A is
antigenically highly variable and is mainly responsible for most cases of epidemics and
pandemics.
1.1.1 Types and Nomenclature
The influenza viruses which belong to the family of Orthomyxoviridae, are characterized
by segmented, negative-strand RNA genomes. There are three types of Influenza viruses,
namely Influenza A, B and C viruses, of which only type A, and B viruses are most
significant as pathogens whereas type C virus is less common and only causes mild
disease in children [6]. Sequencing has confirmed that these viruses share a common
genetic ancestry [7] and electron microscopy reveals that influenza A, and B virus are
virtually indistinguishable.
Influenza A virus (IAV) is further characterized by their subtype of their surface glyco-
protein, the hemagglutinin (HA) and the neuraminidase (NA). Many genetically distinct
subtypes, 18 for HA (H1-H18) and 11 for NA (N1-N11) [8], have been found in the cir-
culating influenza A virus. Many subtypes are specific to birds, some to swine but not
1
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all the resulting IAV subtypes infect humans. Only three HA (H1, H2, H3) and two NA
(N1 and N2) subtype’s combinations are commonly found in humans [8].
Influenza viruses have a standard nomenclature that includes virus type, species from
which it was isolated if on non-humans, location at which it was isolated, isolate num-
ber, isolate year and for IAV virus only, HA and NA subtype. For example, A/Je-
na/5258/2009 (H1N1) was isolate number 5258 of human Influenza A taken in the city
of Jena in 2009 has an HA subtype 1 and NA subtype 1 [9].
1.1.2 Structure and Composition
Influenza virus particles are usually spherical and about 100 nm in diameter, although
the filamentous form also exists and the length can go up to 300 nm. Both influenza A
and B virus genome consisted of eight negative-sense, single stranded viral RNA (vRNA)
segments while influenza C has seven segment genome – lacking the neuraminidase gene.
Sizes and polypeptide assignments are known for the segments (Table 1.1). Most of the
segments code for a single polypeptide protein. The complete nucleotide sequence is
known for many influenza viruses. Interestingly, first 12-13 nucleotides at the end of
each genomic segment are conserved among it’s all eight RNA segments and are very
important in viral transcription [6, 10].
Table 1.1: The genomic segments of influenza A virus and their encoded proteins.
Segment Segment length Encoded Length of polypeptide Function
(# of nucleotides) polypeptide(s) (in amino acids)
1 2341 PB2 759 Polymerase subunit; mRNA cap elongation
(Polymerase basic 2)
2 2341 PB1 757 Polymerase subunit; RNA elongation;
(Polymerase basic 1) endonuclease activity
PB1-N40 718
PB1-F2 87 Pro-apoptotic activity
3 2233 PA 716 Polymerase subunit; protease activity
(Polymerase acidic)
4 1778 HA 550 Surface glycoprotein; mediated virus attachment to cells;
(Hemagglutinin) activated by cleavage; fusion activity at acidic pH
5 1565 NP 498 Associated with RNA and polymerase proteins;
(Nucleoprotein) helical structure; nucleocapsid
6 1413 NA 498 Associated with RNA and polymerase proteins;
(Neuraminidase) helical structure; nucleocapsid
7 1027 M1 252 Major component of virion; lies inside of envelope;
(Matrix protein 1) involved in assemble; interacts with RNPs and NS2
M2 97 Integral membrane protein; ion channel;
(Matrix protein 1) essential for viral uncoating
8 890 NS1 230 Interferon antagonist protein; inhibits pre-mRNA splicing
(nonstructural protein 1)
NS2 121 Minor component of virion; nuclear export of viral
(nonstructural protein 2) ribonucleoproteins (RNPs)
Influenza A virus encodes for twelve polypeptides, out of which only two of them are
non-essential outside the laboratory settings [11, 12]. The nucleoprotein (NP) associates
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with the viral RNA (vRNA) to form a ribonucleoprotein (RNP; 9 nm in diameter), that
assumes a helical configuration and forms the viral nucleocapsid. Three large proteins,
e.g. PB1, PB2, PA, are bound to the viral RNP and are responsible for RNA replication
and transcription. The matrix (M1) protein, which forms a shell underneath the viral
lipid envelope is important for its morphogenesis and is the major component of virion,
about 40% of viral protein.
The virus particles are surrounded by the lipid envelope which is derived from the cell.
The Two glycoproteins, encoded by the vRNA, HA and NA are inserted into the envelope
and are exposed as spikes on the surface of the particle. These two surface glycoproteins
are important antigens, which determine the antigenic variation of influenza viruses and
host immunity. The HA represents about 25% of the viral protein which helps the
virus to recognise N-acetylneuraminic (sialic) acid on the host cell surface [10]. The NA
represents about only 5% of the total protein but are very important for viral release
because of their sialidase activity. The M2 ion-channel protein as well as NS2 (nuclear
export protein; NEP) are also present in the envelope but at only few copies per particle
[6, 10].
1.1.3 Transmission
The transmission of the disease-causing influenza virus occurs in three ways: 1) by
direct contact with infected individuals; 2) by contact with the contaminated objects;
3) by airborne infection, aerosols [8, 13]. The influenza virus shedding begins the day
before symptoms appear and efficient virus shedding to continues until five to seven days.
Nasal secretions, which contain virus particles, are responsible for transmission by direct
contact or by contaminated objects. An infected person will frequently touch their nose
or conjunctiva, placing the virus on the hand. Intimate or non-intimate contact (e.g.
shaking hands) will transfer the virus to another person, who will then infect themselves
by touching their nose or eyes [8].
Respiratory transmission depends upon the production of fine aerosols that contain virus
particles. Coughing from an infected individual may produce several hundred droplets,
a good sneeze can generate up to 20,000 particles [13, 14]. Droplets of 1-4 microns in
diameter are called droplet nuclei, these stays in the air for very long period of time
and these droplets nuclei not only travel long distances, but can also reach the lower
respiratory tract. Inhalation of droplets and droplet nuclei places a virus in the upper
respiratory tract, where they initiate infection. Influenza transmission can be reduced
by covering nose and mouth when coughing or sneezing, and by washing hands often
with soap and water or alcohol-based hand cleaners. [8, 13, 14]
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1.1.4 Symptoms
Symptoms of classical influenza usually appear between 18 and 72 hours post infection
and include chills, headache, and dry cough, followed by fever. Other symptoms includes
muscle and joint aches, sore throat, runny nose, nausea and anorexia [8, 10].
The virus can spread throughout the entire respiratory tract and thus, the bronchi, the
lower trachea and the lungs become infected. The degeneration and deaths of infected
cell are a prerequisite for the bacterial super-infection. This usually occurs after two
to three days after the onset of influenza infection and can significantly prolong the
course of respiratory infection. The most common bacteria that cause super-infection are
Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae [15, 16].
Influenza infections can also be asymptomatic or only mild symptoms like the running
flu while the other extreme are very severe cases, to death.
1.1.5 Seasonality, Epidemics and Pandemics
Influenza viruses are remarkable in nature because of their frequent antigenic changes
that occur in HA and NA. The two surface antigens or surface glycoproteins of influenza
undergo antigenic variations independent of each other. Minor antigenic variations are
called as antigenic drift (characteristic of all three influenza viruses) whereas major
antigenic changes in HA and NA are called as an antigenic shift (characteristic feature
of only influenza A virus) which results in the appearance of a novel subtype. Antigenic
shift is most likely ended up in an epidemics or even pandemics. Antigenic drift is due to
the accumulation of point mutation in the gene, which results in changes in amino acid
of the protein. Antigenic drift reflects drastic changes of the viral surface glycoproteins
due to reassortment of viral genome segment. The segmented genomes of influenza virus
reassort readily in double infected cells, for example cells infected with H1N1 and H3N2.
Typically, influenza epidemics occur abruptly, reaching their peak within two to three
weeks and last for approximately five to six weeks. Prolonged epidemics can occur by ei-
ther successive or overlapping waves of infection of different virus types. The pandemics,
i.e. global epidemics with high morbidity and mortality, may occur when a new virus
subtype or variant is formed by the antigenic shift against the population lacking immu-
nity against it. In 20th century, globally there were three influenza pandemics caused by
genetic modification of influenza A virus, this happened in 1918-19 (H1N1) [17], 1957-
58 (H2N2) [18], 1968-69 (H3N2) [19]. The most severe pandemic was in the winter of
1918-1919, the so-called Spanish influenza (A/H1N1), killed around 40-50 million people
[20]. The biological basis for the increased severity of some influenza viruses remains
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unclear. Unpredicted mutations which leads to intra-host evolution of quasi-species [2],
and strong inflammation are important hallmarks of severe pandemic influenza infection
[1, 11, 21–23].
1.2 Mathematical Modelling
In science, a model is generally considered either as a part of a or a representation,
of a system that we aim to study, while modelling is an attempt to describe a better
understanding of the elements of the systems, their states and their interaction with
other elements. A mathematical model represents the examined systems (dynamics, for
instance) in the form of various types of equations, often consists of differential equations,
which intend to understand the system. The model should be defined precisely to include
key elements, which can, in principle, be used to simulate the behaviour of the system on
a computer. For example, a model can be used to describe relatively low-level molecular
biology processes like transcription, translation, gene regulation, cellular signalling and
so on. Moreover, it can be used at higher level describing the behaviour and evolution
of population of individual organism. In addition, mathematical modelling plays a far
more important role, especially in the studies of dynamics of infectious agents and have
proven to be useful tools in the analysis of viral infections [24–31]. For instance, the
dynamics of human deficiency virus (HIV) infections were poorly understood until simple
mathematical models were developed. These models could help in estimating the rate
of HIV replication, the number of virus particles produced and cleared daily, and the
average life span of productively infected CD4+T cells [25, 26].
Emergence of new influenza virus strain via genome reassortment or the emergence of
antibiotic-resistant strain of influenza, both keep a general interest in infectious diseases
and their control going. Mathematical modelling of infectious disease has a long history
in mathematical biology. The first mathematical model that could be used to describe
an influenza virus dynamics within a single infected host dated back in 1976 [24]. A
compartmental model was used to describe the dynamics of influenza virus within in-
fected mice, further details about mathematical modelling and their advancement can
be found in the next sections.
1.2.1 State Variables and Model parameters
The primary components of a mathematical model correspond to the elements involved
in the systems. The abundance of each element is assigned to a state variable within
the model. The collection of all these state variables is called as the state of the system. It
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gives us a complete description of the events or system’s condition at any particular time.
The model’s dynamics behaviour is the time course for the collection of state variable.
Besides variables of state, mathematical models also include parameters, whose values
are sometimes fixed but can be estimated with various optimization algorithms [32].
Model parameters define the interaction between the elements of the systems and with
the environment. For example, model parameters are: degradation rate, replication rate,
carrying capacity of a pathogen and so on. A change in the value of a model parameter
corresponds to a change in the environmental or in the systems itself. As a result,
model’s parameters are typically held constant during model simulation. These values
can be varied to explore systems behaviour under different experimental conditions.
1.2.2 Linearity and Non-linearity
A relationship is called as linear if it is of a direct proportionality or relationship. For
example, the variable x and y are linearly related by the equation x = ky, where k is a
fixed constant. Linearity allows for an effortless extrapolation, which means doubling of
x will lead to doubling of y regardless of their values. A dynamic mathematical model
is called as linear if all interactions among its components are of linear relationships.
However, sometimes it is a highly restrictive condition, and as a result they display
only a limited range of behaviour. For example, the rate of replication or growth of
bacteria in a cell culture medium is directly proportional to the continuous availability
of resources in the medium.
Any relationship that is not linear is referred to as non-linear. Non-linear relations
need not to follow any specific pattern and so are difficult to address any generality. The
non-linearities that appear most often are saturations, in which one variables increases
with another variable at a diminishing rate, so that the dependent variable tends to a
limiting value. Two kinds of saturating relationship that occur most often are hyberbolic
saturation, in which the rate of the increase of one variable declines continuously as the
value of other variable increases. Secondly, the sigmoidal saturation, where one variable
initially grows slowly with another variable, then passes through a phase of rapid growth
before saturating.
1.2.3 Stochastic and Deterministic Models
There are two types of models that are useful in the study of the infectious diseases at
the population scale: these are stochastic and deterministic models.
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Stochastic models rely on chance variation in risks of exposure, disease, and other factors
[33]. They give us much more insight into an individual-level modelling, such as, taking
into consideration small population size where every individual play a significant role
in the model. Therefore, they are used when known heterogeneities are important as
in small or isolated populations. Stochastic models have several advantages. More
specifically, they can allow close watching of each individual in the population on a
chance basis. However, sometimes they can be more laborious to set up and need many
simulations to yield useful predictions. These models can become mathematically very
complex, take more computational time and do not contribute to an explanation of the
dynamics.
However, Deterministic models, which are also called as a compartmental model, at-
tempts to describe and explains what happens to the mean at the population scale
instead on an individual scale. They fit well to large populations. These models cate-
gorises individuals into different sub groups/compartments, such as, SIR model consists
of three compartments represented by Susceptible, Infectious and Recovered [34]. The
infection or the attack rate is defined as the best transition rate, how the size of one
compartment changes with respect to the other, which measures the rate at which sus-
ceptible becomes infected.
Most of the mathematical model which have been used, until now, to describe the be-
haviour of infectious disease are deterministic as they require less data, relatively easy
to set up, many computer software’s are readily available and user-friendly. Therefore,
deterministic models are commonly used to explore whether a particular control strategy
will be effective or not, because of the well understanding of the SIR model. Further-
more, many other more complex models exist that can incorporate stochastic elements.
However, in my thesis, I will focus more on the deterministic models.
1.2.4 Basic Viral Dynamics Model
Perelson [27] has described a basic model, which has been used to study human immuno-
deficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV). The basic
model of viral infection dynamics was based on the classic SIR model. Target cells (T ),
which are susceptible to infection are infected by the virus (V ) to become infected I by
a constant rate of κ. Whereas, target cells are assumed to be continuously produced
from a source by a constant rate of λ and these cells have a natural death rate at d per
cell.
Each infected cell is assumed to produce new virus particles at a constant average rate ρ
per cell. The newly produced virus particles can either infect new healthy cells at a rate
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κ as explained above or get cleared from the body at rate c per virion, which corresponds
to a half-life t1/2 = ln(2)/c. An infected cell has an average lifespan of 1/δ, where δ
corresponds to the death rate of infected cells, thus, producing an average of N = ρ/δ
virions during its lifetime. Fig. 1.1 shows a schematic diagram of these dynamics, and
the associated ordinary differential equations are given Eq. 1.1.
dT
dt
= λ− dT − κV T (1)
dI
dt
= κV T − δI (2)
dV
dt
= ρ− cV (3)
(1.1)
However, the classic model of influenza dynamics has been modified to a more accurate
representation of the infection dynamics as influenza infections are quite rapid, lasting
approximately 7-10 days. The eclipse phase, i.e., the time it takes for viral production to
begin after intially becoming infected, was incorporated into the models by including a
second class of infected cells (I1) that are in eclipse phase and cannot yet produce virus.
One class of these models are based on the assumption that the cells in the eclipse state
(I1) transformed to a productive state (I2) at rate k and no cell death occurs before
the initiation of virus production. While in other classes, the time spent in the eclipse
phase is described by either a fixed or distributed delay [29, 35]. In general, including
the eclipse phase does not change the model behaviour and may not be statistically
justifiable since the number of parameters are increased [36]. However, when taking
these dynamics into account, the parameter estimates made by fitting the model to data
enter more biologically realistic ranges [28, 29] and growth kinetics are more accurate
[30].
The virus lost from entry into cells is typically ignored in viral kinetic’s models, as shown
above. Since, this is usually a negligible quantity in comparison with the amount lost by
other processes such as phagocytosis. Furthermore, in influenza infection, particularly,
it is typical to measure only infectious virus. Therefore, loss of viral infectivity can be
modeled as clearance of infectious virus. This has been shown by Beauchemin et al [29],
where the parameter estimated using viral titres from infection of MDCK cells in vitro
suggested that the loss of viral infectivity is much smaller than the loss of virus from
cell entry.
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Figure 1.1: A basic viral infection dynamic model proposed by Perelson [27]. The
model variables T (Target cells), I (Infected cells) and V (Virions) as well as their
relations between them are shown in Eq. 1.1.
1.2.5 Application of Mathematical modelling for Understanding In-
fluenza Kinetics
Characterising influenza infection kinetics using data fitting and models to estimate
parameter is an effective technique, but obtaining an accurate model in which all pa-
rameters are identifiable is challenging. The classic model as discussed above in Fig.
1.1 has 3 equations and 8 parameters for which nonlinear least squares or the maximum
likelihood analog are the most frequently used methods to establish parameter values.
However, not all the parameters are identifiable [32] and it has been necessary to fix
some parameters or restrict the ratios of parameters to ensure they take on biologically
relevant values. Modelling and data fitting techniques allow estimation of parameters
characterising viral infection. At the same time, model structure can be wrong, error
in parameter estimation can occur and different fitting methods can yield distinctive
parameters estimates [37, 38], and also multiple solutions because of local optima might
confound non linear least square or maximum likelihood fitting.
A number of mathematical models have been proposed, which are dealing with the
dynamics of influenza viruses and have been proven to be useful tools in the analysis of
influenza and other viral infections [22, 24–28, 31, 39–42]. In contrast, the extremely fast
and relatively short duration of replication of influenza A virus in immunocompetent
adults invites the search for alternative views of influenza virus and immune system
dynamics [28]. Many mathematical models have been developed for influenza virus,
where viral titres (viral factors) [24, 28] and/or measurements of at least, one of the
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immunological components of hosts [22, 31, 39–42] , like interferons, macrophages, NK
cells, B and T cells, were used as experimental data to model the influenza kinetics
in different hosts. A study by Larson [24] used a compartmental modelling approach
to describe the influenza virus dynamics. However, they did not consider any immune
population or factors, so changes in the viral population cannot be connected with any
immune response.
The first mathematical model of influenza kinetics to take experimental data into account
was proposed by Baccam et al. [28]. Data was taken from experimental infection of
volunteers with a seasonal strain of influenza virus, which follows the typical course of
an uncomplicated influenza infection, A/Hong King/123/77 (H1N1). Nasal washes were
collected daily and serially cultures in 10-fold dilutions to determine viral titres. The
simple mathematical model used to describe the kinetic of infection is given by Eq. 1.2:
dT
dt
= −βTV
dE
dt
= βTV − kE
dI
dt
= kE − δI
dV
dt
= ρI − cV
(1.2)
Where susceptible cells, T, can be infected by virus, V, becoming infected cells, I at a
rate β. Infected cells produce virus at a rate ρ and die at a rate δ, while virions are
cleared at a rate c. Infection is initiated by introducing an initial inoculation of virus
V0 to a population of susceptible target cells T0. The main limitation of the model was
that the effect of immune systems was not explicitly accounted for the virus clearance.
Therefore, the model was target-cell limited, which means once the infection has spread.
It will only stop until population of target cells has been entirely eliminated by the
infection.
Recent models have used approached similar to Baccum et al [28], in order to capture the
dynamics of influenza infection using experimental data. Models have been developed to
include the effect of the immune response to an influenza infection by comparing models
to experimental viral load data and immune response data [22, 31, 39–42].
Another mathematical model attempted to fully characterize the behaviour of within-
host influenza infection by taking into account, a substantial immune response [31].
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The model consists of 13 variables, representing the virus, epithelial cells and various
immune responses, and the behaviour is characterized by more than 60 parameters.
Parameter values were estimated from experimental data, and an attempt was made
to account for experimentally known infection dynamics, such as estimates of immune
system activation, proliferation and decay rates at various times post-infection. However,
the results of the model were not compared with experimental viral load or immune
response data. Isolating the role of specific immune effects also proved difficult, due
to the large number of parameters. Hancioglu et al., [39] developed a model consisting
of 10 equations and 27 parameters, but the results were also not directly compared to
experimental data due to the difficulty and cost in procuring such extensive viral and host
immune response data. Moreover, the model was too complexed and needs more data
to estimate the parameters. Pawelek [42] fitted the within−host viral dynamics model
to the data derived from six ponies infected with an influenza virus A/eq/Kildare/89
(H3N8). They showed that both innate and adaptive immune response is needed for the
viral clearance.
In a review by Smith and Perelson [36], they mentioned about the increasing number of
influenza kinetics models based on viral load data and also showed concern about using
such data as the only indicator of disease severity. However, immunopathology also plays
some role in severe infection [1, 21, 43–46]. For example, Kumar et al., [46] has shown
that a strong late immune response can increase the risk of persistent inflammation
even after clearing the pathogen. Interestingly, Smith and Perelson [47] suggest that
assigning a symptom score throughout the infection could offer a new perspective into
the characteristics of an infection. A symptom score is easily attainable and reflects how
sick a host is [48].
Both small−scale mathematical models [28, 49] and complex models with larger than 10
equations with larger than 50 parameters [24, 39, 50] have been proposed for studying
influenza A infection dynamics. However, complex models require an increased number
and quality of experimental data to calibrate the model parameters. Small−scale models
have the advantage to be applicable for quantitative comparison of a (also large) set
of experiments (e.g., with different virus strains and/or therapeutic strategies) with a
limited experimental effort.
Furthermore, studying influenza dynamics invitro have strengthened the understanding
of viral production and clearance rates. Understanding the differences in the pathogenic-
ity of virus strains is important aspects of influenza biology. Modelling influenza kinetics
played an integral role in teasing apart the differences and potential mechanism of a vir-
ulent influenza strain compared to a less pathogenic one [47]. However, until now, none
of the models have been used to fit the data to quantify different influenza viruses. In
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my thesis, I have developed a small-scale mathematical model by using the symptom
score as an easily attainable data source. The small-scale model could fit the data of four
different influenza virus strains and able to quantify them based on their pathogenicity
of infection from severe to mild to weaker. Virus pathogenicity, antiviral immune de-
fence, and pro−inflammatory response were considered as the main model variables in
a three-dimensional differential equation model.
1.3 Gene Expression Microarrays
1.3.1 Overview of DNA and RNA
Deoxyribonucleic acid (DNA) encodes the information required for the development and
function of a living organism. The structure of DNA is remarkably simple, being formed
of a long chain of smaller units (nucleotides) joined together. Each nucleotide can have
one of four bases attached; Adenine (A), Cytosine (C) Thymine (T) or Guanine (G),
however, in case of Ribonucleic Acid (RNA) has a Uracil (U) base instead of T. The
order in which these bases occur in a DNA and RNA molecule is known as the DNA
and RNA sequences respectively.
Structurally, a DNA molecule takes the form of a double helix arranged by two strands of
DNA. This structure is held together by strong hydrogen bonds between the two strands.
The bonding takes place in such a way that A base-pairs with a T base whereas C base-
pairs with G, in the opposite strand. This is known as the base complementarity property
of DNA and effectively means that the sequence of one strand can be determined by the
other, a fact that is exploited during DNA replication.
The entire DNA sequence of an organism is known as its genome. The human genome
is estimated to have 3.3 billion bases and can be found in the nucleus of every cell
in the body. Rather than being one long DNA molecule, a genome is divided into
continuous regions of DNA known as chromosomes. There are 24 chromosomes in the
human genome, which are numbered from 1 to 22 plus the sex chromosomes, X and Y.
Therefore, the normal healthy cells in the human body contain 46 chromosomes, i.e., two
copies of 1 to 22 chromosome (each copy from one parent) and either X and Y for males
or X and X for females. Each chromosome is divided into stretches of DNA called genes,
which encode the instructions to produce a particular protein. The estimate number of
protein-coding genes that the human genome has around 20,000 [51]. However, rather
than being one continuous sequence of genes, there are many gaps in the chromosome
that are not genes and hence do not code for proteins. In fact, only an estimated 5 to
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10% of our genome is used to code for proteins. The purpose of remaining “junk DNA”
is a source of much debate, but increasingly is considered to have regulatory function.
The information encoded in the DNA sequence are stored in the nucleus and must be
transported to the cytoplasm, where specialised molecules called ribosomes help produce
the required proteins. Therefore, sections of DNA are copied i.e. transcribed into
messenger RNA (mRNA) molecules that contain the same information as DNA (as
in complementary DNA), but in a slightly different form. The main differences are
that mRNA is single-stranded, degrades quickly. The entire sequence of each gene is
transcribed, even though not all parts of the sequence take part in coding for proteins.
Such non-coding regions, known as introns, are removed by splicing before the process
of translation starts. Translation uses mRNA as a template to assemble previously
synthesised amino acids in the correct order to make particular proteins, with groups of
3 successive bases used to specify the amino acid located at that position in the chain.
Although each cell contains copies of the same genome, the cell will require different
combinations as well as distinctive quantity of protein in order to perform its activity
within the body. Therefore, the genes that control the production of these proteins may
be turned on or off to varying degrees, depending on the internal and external stimuli.
These changes confer unique properties to each cell type. The expression level of a
gene refers to the amount of mRNA that is made from the DNA template and finally
translated into the required proteins.
1.3.2 Gene Expression Microarrays
A microarray, sometimes called as an array, is an experimental technique for simultane-
ously measuring the expression level of genes ranging from few hundred genes to whole
genome. The technology makes use of the base-complementarity property of DNA and
the fact that single-stranded mRNA is produced in order for a particular gene to be ex-
pressed. Thus, by measuring the amount of mRNA produced we can infer the expression
level of the genes involved.
Microarrays are typically constructed by attaching single-stranded DNA sequences,
known as probes, to a surface such as a glass slide. Each probe is complementary
to the DNA sequence of a particular gene of interest and is placed in spots (or features)
at pre-defined locations. Single stranded mRNA from a sample of interest (called the
target) is isolated, converted into single stranded DNA (cDNA) and then transcribed
into cRNA. These cRNA are next fluorescently labelled, and exposed to the microarray
surface. The target RNA then hybridises to its complementary probe sequence on the
microarray, whereas non-complementary sequences should fail to hybridise.
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The amount of fluorescence observed at each feature can therefore be used to determine
the level of expression for each of the genes represented on the array. In the earliest
microarrays [52], each feature on the array corresponded to a different gene of interest.
However, subsequent developments in microarray production have allowed the same gene
to be represented multiple times, thus providing more reliable expression estimates.
Two colour microarrays are used to compare two samples, i.e. control versus treated,
on the same microarray. The RNA from the two samples is extracted separately and
fluorescently labelled with different dyes, usually red (Cy3) for treated and green (Cy5)
for control. Therefore, after hybridisation, each feature is a mixture of red and green
fluorescences. A completely red or green feature represents that the particular gene is
expressed in one sample, but not in other. Practically, the mixture of red and green
fluorescence features are not so clear cut that the statistical methods are required to
quantify the contributions of each colour. A differential expression analysis aims to
figure out, which genes have significantly different expression levels between different
experimental conditions under investigation. Such genes are said to be differentially
expressed genes (DEGs). See Fig. 1.2 for schematic representation of a typical two
colour microarray experiment.
On the other hand, single-channel microarray can also be produced to measure the
absolute expression level of every gene of interest in a particular sample. Therefore, the
fluorescence intensity of each feature is a measure of the expression level of a particular
gene. The most popular single-channel microarray technology was that of Affymetrix
[53]. These arrays use 25 base-pair probes that are synthesised onto the array surface
and each gene is interrogated by a collection of probe pairs, usually 11-20, and are known
as probe set.
Microarrays have become an invaluable tool for medical research [54] and provide a
great wealth of data that was previously unobtainable. Additionally, microarrays are
manufactured for application other than genome expression. For instance, microarrays
can be used to interrogate genome-wide association studies like Single Nucleotide Poly-
morphism (SNP) and structural variation like methylation, which alter the structure of
DNA but not the sequence.
1.3.3 Illumina Bead-based Microarrays
In my thesis, I will concentrate on the BeadArray microarray technology which is devel-
oped by Illumina, and is becoming widely used and offers many potential benefits over
other technologies. Rather than attaching probes onto a microarray at known locations,
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Figure 1.2: A typical two colour microarray experiment to compare mRNA expression
between a diseased condition to that of a normal condition.
BeadArrays are self-assembling arrays of minute beads with probes attached. Each ar-
ray is produced separately by exposing an array surface, either a planar silica slide or
fibre-optic bundle, to a large collection of pre-prepared beads. This causes the beads to
be randomly sampled and assembled into the microwells on the surface of the array slide
[55]. When randomly assembled at the slide surface, the beads have a uniform spac-
ing of ≈ 5.7 microns. Each bead is 3 microns in diameter and covered with a specific
type of oligonucleotide in many hundreds of thousands copies. Both the number and
location of the replicates for the same bead type is random on an array [56]. Therefore,
an extra label sequence, an Illumina code, is attached to each bead for decoding [57],
with beads of same type also having the same Illumina code. Each Illumina code is
designed to hybridise in a predictable way to a series of specially designed dye-labelled
sequences. After each hybridisation, each bead is assigned to either of the two states,
i.e., red/treated or green/control, depending on the amount of hybridisation, a binary
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sequence is determined for each bead. This binary sequence should then uniquely corre-
spond to the predicted response of an Illumina code. These decoding hybridisation are
done by Illumina, in order to get that no array will be supplied to the user with a bead
type that has less than five replicates.
Along with the high degree of replication within an array, Illumina also offers the capa-
bility of processing BeadArrays in parallel, making this technology highly desirable for
high-throughput experiments. A Sentrix BeadChip is a glass slide that allows a very
high number of observations to be made for a particular sample. Depending on the chip
configuration, 1 to 16 samples can be processed simultaneously with tens of thousands
of genes profiled per sample. The Sentrix Array Matrix (SAM) contains 96 arrays, each
of which us a hexagonal fibre-optic bundle with approximately 50,000 beads and 1,500
distinct bead types. Thus, a 96 samples can be examined simultaneously on a single
SAM.
1.3.4 Applications of Illumina Microarrays in Systems Biology of In-
fluenza Virus.
Expression profiling studies aims to deduce the expression level of many thousands
genes simultaneously under different conditions of interest. In a simple scenario, one
might try to find genes that have a distinct differential expression between normal and
diseased tissue condition. In order to avoid biases of the expression data result, it is
important to make the measurement for all possible genes and to have to replicate for
the sample of interest. This is extremely crucial when we are investigating a system
for which a little prior knowledge is available. A most popular use of microarray is in
studies of disease dynamics, where one might get insights into the disease dynamics at
the molecular level. Illumina expression arrays provide a good opportunity to measure
a very large number of transcripts at once, giving researchers a detailed picture of gene
expression in their sample of interest. The ability to make 30 observations for a specific
gene of interest is of prime advantage, which might reduce some of the measurement
errors inherent in microarrays. As the replicates of a specific gene of interest is spread
over the array surface, minimising the effects of spatial artefacts. Moreover, the probe
sequences are attached to beads rather than the array surface. Therefore, hybridisation
should only take place at the bead level and the area between the beads shows no
fluorescence. Hence, we would expect the background level to be low and consistent on
the array surface. BeadArrays also provides reliable estimates of mean and variances
across samples because of not only they provide more replicates of a particular gene on
one array but their ability to process more arrays in parallel. Furthermore, by being
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able to hybridise and scan multiple arrays simultaneously, we would hope to reduce the
batch effects associated with running microarrays on different days.
The first step to a systems biology approach is the data assembly, which should be as
extensive as possible. Investigating the molecular mechanisms of the severe influenza is
important in controlling complications and reducing the pulmonary damage in the host.
Comprehensive genome wide expression data involving both innate as well as adaptive
immune response might help to understand the role of host’s response during influenza
virus infection. In recent years, many whole genome expression changes analysis has been
studied in lungs of mice, and other model organisms [45, 58] after infection with different
influenza viruses (including different IAV subtypes) causing mild or severe disease [1,
59–62]. All most all the studies so far have focussed on the innate immune response
of the host. Until now, only one study integrated both innate and adaptive immune
response, and described different phases of disease as temporal changes in gene expression
profile in lungs of mice [59]. Moreover, there is no study, which correlates the gene
expression profile data with the clinical outcomes or the phenotype data and to explain
severe influenza with the biphasic course of disease. Recently, we used mathematical
modelling to explain the biphasic course of influenza caused by the A(H1N1)pdm09
isolate Jena/5258 and suggested the second disease peak was due to high inflammation
[22]. However, we failed to show the dynamics behind it due to the limited amount of
data. Further experimental studies with mpJena/5258 in mice after demonstrated a fast
intra-host evolution of the virus based on HA-222D/G polymorphism [2]. Viral evolution
was accompanied with changes in organ tropism and different antibody recognition that
could be one of the reasons for second peak of the body weight change and clinical score
observed during the second lung passage of the virus [2]. Furthermore, a very strong lung
histopathology was observed underlining the suggestion on the impact of inflammation.
In my thesis, I have performed a comprehensive analysis of whole genome expression
changes of the lung of mice infected with the pH1N1 mpJena/5258 consisting HA-
222D/G quasispecies to gain insights into pathogenesis at the transcriptional level. We
studied both, the innate and adaptive host immune response in order to identify key
regulatory interactions during infection. A reverse engineering strategy was applied to
infer a gene regulatory network. Since the complexity of network structure increases
with the number of genes, a small number of 20 differentially expressed genes (DEGs)
was selected to be included in the network. In order to identify key genes, we per-
formed functional categorization and identified significantly overrepresented functional
categories.
Chapter 2
Materials and Methods
2.1 Phenomological Data
The pathogenicity of influenza viruses, A/Jena/5258/09 (Jena/5258), A/Jena/5555/09
(Jena/5555), A/Jena/2688/10 (Jena/2688) and European A/swine/Bakum/1832/00 (H1
N2) (Bakum/1832), were compared in BALB/c mice at the Jena University Hospital,
department of Virology and Antiviral Therapy, Jena as described recently in Manchanda
et al, [22].
Figure 2.1: Pictorial representation of experimental setup. The mice were intranasally
infected separately with 106 TCID50/20µl dose of 4 different influenza virus strains.
The body weight loss change as well as clinical symptom score were observed for 21
days post infection.
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Briefly, the A(H1N1)pdm09 influenza virus strains, Jena/5258, Jena/5555 and Jena/2688
were isolated in MDCK cells from respiratory specimen that originated from patients
with clinical symptoms of influenza infection. The European swine H1N2 influenza virus,
Bakum/1832, was obtained from a nasan swab of a diseased pig [63, 64]. Experiments
were performed in female BALB/c mice, weighing 16-18g as shown in Fig. 2.1. After
isoflurane anesthesia, five mice were inoculated intranasally with 106 TCID50/20µl of
each virus in EMEM and three mice were mock infected for control.
Body weight and clinical symptoms score were monitored for 21 days after virus infec-
tion. Mice that lost more that 25% of the body weight of their initial body weight were
sacrificed and the clinical score of 7 were given to them. A laboratory clinical symptom
score was used to assess the severity of the disease. It ranged from 0 to 7, while scoring
Figure 2.2: The general clinical scoring system, The score ranges between 0 to 7, while
scoring is based on smooth coat, clear eyes and physically activity of mice. The pho-
tographs were kindly provided by the Jena University Hospital, department of Virology
and Antiviral Therapy, Jena.
is based on smooth coat, clear eyes and physical activity of mice as shown in Fig. 2.2
and following:
1. scrubby coat in the neck
2. scrubby coat in the neck and on the back
3. scrubby coat on whole body, incipient hunchbacked posture
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4. scrubby coat, hunchback posture, inactivity, eyes half closed
5. scrubby coat, hunchback posture, inactivity, eyes closed
6. scrubby coat, hunchback posture, completely inactive, eyes closed
7. mouse deceased or lost more than 25% of initial body weight
Interestingly, Smith and Perelson [36] suggests that using a clinical symptom score
throughout the infection process could offer a new perspective into the characteristics
of an infection. As symptoms score is easily obtainable and reflects how sick a host is.
The mean values and standard deviation for the clinical symptom score (S) as well as
Body weight changes in comparison to control were calculated and shown in Fig. 2.3
and Fig. 2.4 respectively.
Figure 2.3: Clinical symptoms score for mice infected with four different influenza
virus strains. Top left: A(H1N1)pdm09 Jena/5258; top right: (H1N1)pdm09 Je-
na/5555; bottom left: (H1N1)pdm10 Jena/2688; bottom right: European swine H1N2
Bakum/1832 (full squares).
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Figure 2.4: Body weight changes after infection with different virus strains. Top
left: A(H1N1)pdm09 Jena/5258; top right: (H1N1)pdm09 Jena/5555; bottom left:
(H1N1)pdm10 Jena/2688; bottom right: European swine H1N2 Bakum/1832 compared
with uninfected mice.  represents data for virus infection whereas × represents data
for uninfected control mice.
2.2 Gene Expression Microarray Data
The study design of the animal experiment was described elsewhere [2] and experiments
were performed by PD Dr. Michaela’s group at Institute of Virology and Antiviral
Therapy (IVAT), Jena University Hospital. Briefly, 7- to 8-week-old female BALB/c
mice (16 – 18 g; Charles River, Bad Sulzfeld, Germany) were infected intranasally with
106 TCID50/20 µl of the influenzavirus mpJena/5258 under isoflurane anesthesia. Mock-
infected mice were used as control. Five to 10 mpJena/5258-infected mice were sacrificed
on day 1-7, 9 and 12 p.i. The left lung lobe was fixed in formalin and used to evaluate
lung pathology after hematoxiln-eosin staining [2]. One of the right lung lobe was
frozen for RNA analysis in RNAlater stabilization solution (Ambion by Life technologies,
Darmstadt, Germany).
The microarray experiments were performed in the lab of Dr. Ralf Claus at Department
of Anaesthesiology and Intensive Care Medicine, University Hospital Jena. Briefly, prior
to gene expression experiments total RNA integrity was confirmed using the ExperionTM
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automated gel electrophoresis system (BioRad, Munich, Germany). cRNA sample
preparation for hybridisation on the Illumina gene expression platform was performed
using the TargetAmpTM Nano-gTM Biotin-aRNA Kit for the IlluminaTM System (Epi-
centre/Biozym, Hess. Oldendorf, Germany) starting with 250 ng of totalRNA. Samples
were hybridised according to manufacturer instructions on Mouse Ref-8 v2.0 Bead Chips
(Illumina, San Diego, USA). Each chip is comprising probes of 25700 coding and non
coding RNA transcripts. Read outs of hybridisation signal intensities were performed
on an iScan Bead Array scanner (Illumina, San Diego, USA), data pre-processing in-
cluding spot detection, gene mapping and averaging of replicates was performed with
iScan Control Software and GenomeStudio software (Illumina, San Diego).
2.3 Mathematical Modelling
2.3.1 Mathematical Model Notation
The mathematical model representing the within-host influenza dynamics consists of
a system of three differential equations in which the dependent variables represent the
virus pathogenicity (P), antiviral immune defense (D) including both the innate immune
response and the adaptive immune response, and inflammation due to pro-inflammatory
response (I). The mathematical equations of our reduced model are:
dP
dt
= αP
(
1− P
kp
)
− βD
( P
P + 0.01
)
dD
dt
= γP − θD
dI
dt
= f(D)− ρI
f(D) = 1 + tanh
(D − δ
ω
)
S = P + I
(2.1)
The virus pathogenicity P represents the virulence of the virus strains. The dynamics
of change of P is described by eq. 2.1. It depends on viral infection and the immune
response of the host. The first term is parameterized by the virus infection rate (param-
eterized by α) and the maximum primary pathogenicity (parameterized by kP ). The
second term of eq. 2.1 represents the efficiency of the early immune response to the
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virus (parameterized by β). For very small values of P this second term goes to zero due
to the Michaelis-Menten function parameterized by a small and fixed Michaelis-Menten
constant 0.01 (smaller values or other functions that go to zero if P becomes zero do not
change the model behavior) to avoid that P becomes negative.
Figure 2.5: Pictorial representation of mathematical model developed for Influenza
dynamics. The model variables P (pathogen), D (defense), I (inflammation), and
S (clinical score) as well as the relations between them according to Equations 2.1
The antiviral defense is modeled by the variable D including both the innate immune
response and the adaptive immune response. Although the defense system is very com-
plex, in the small-scale model the change of the defense system is modeled in eq. 2.1
by only two terms. The first term represents the activation of the defense systems in
response to the pathogen (parameterized by γ), and the second term represents the
immunity decay (parameterized by θ), which means that once the pathogen has been
cleared off from the host system, the defense system should come to rest. Both terms
are modeled by first-order reactions.
The third model variable I represents the inflammation due to pro-inflammatory re-
sponse. Its change is described by eq. 2.1. This model formulation is derived from
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Table 2.1: Description of model variables and parameters.
Model Variables
t Time (d)
P Virus pathogenicity
D Antiviral immune defense
I Inflammation due to pro-inflammatory response
S Clinical Score (measure of clinical symptoms)
Model Parameters Description Value
α Viral infection rate Estimated (d−1)
kP Maximum primary pathogenicity Estimated
β Efficiency of immune response Fixed: 1 d−1,
see text 3.1.1
γ Rate of activation of immune response Estimated (d−1)
θ Convalescence rate of immune defense Fixed: 0.01 d−1,
see text 3.1.1
 Inflammation activation rate Estimated (d−1)
δ Triggering threshold values of the defense Estimated for biphasic
for pro-inflammation course only
ω Tolerance value of the defense for the Estimated
chronic inflammation
ρ Relaxation rate of inflammatory response Fixed: 1.82 d−1 [48]
or Anti-inflammatory response
P(0) Viral Pathogenicity, initial value Fixed: 0.01 [28]
D(0) Antiviral immune defense, initial value Fixed: 0.00
I(0) Inflammation due to pro-inflammatory response, Fixed: 0.00
initial value
Kumar et al. [46], and describes a combined effect of cytokines and chemokines, and
stimulatory effects of tissue damaged and dysfunction.The first term according to Kumar
et al. is a hyperbolic function of antiviral defense system of the host D which strength
is parameterized by . The parameter δ represents the triggering threshold value for
the chronic inflammation along with the parameter ω, which represents the strength
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of prolongation of the inflammation. The ratio of δ/ω represents the intensity of the
inflammation which can explain whether the virus triggers the chronic inflammation
or the acute one. The second term in I represents the relaxation of the inflammation
(parameterized by ρ) which could be the anti inflammatory response by the host. This
part of inflammation (denoted by I) does not help in removing the pathogen but leads to
collateral damage to the neighboring tissue [1, 43, 65–67] contributing to the influenza
virus-induced symptoms (clinical score S) as modelled by S. Fig. 2.5 displays the model
structure and Table 2.1 lists the model parameters.
2.3.2 Model Simulation and Parameters Optimisation
The model formulated by the Eqs. (1)–(5) in 2.1 is numerically solved using the R-
package deSolve from Soetaert [68]. The LSODA method of integration was employed
using a step size of 0.01. The R-package FME from Soetaert [69] was used for the
estimation of parameter values and their impact (sensitivity) on the model output S.
The Levenberg–Marquardt algorithm from More´ [70] has been used to fit the model
variable S to the respective data (observed clinical score) as implemented in the modFit
function of the package FME. The modCost function from the package has been used in
the fitting procedure and is the sum of the variable costs, which are scaled according to
the number of observations. The variables cost itself is calculated as the sum of squared
weighted residuals, where the standard deviation Std of the mean of the observed clinical
score S is used as weight.
Finally, a Markov Chain Monte Carlo (MCMC; implemented in the package FME [69])
simulation was used to estimate the uncertainty of the parameter estimates as resulted
by the model fit. The first 500 iterations were removed which is known as burn-in so as
to make sure the chain was close enough to target distribution. The parameters sets that
gave the highest probability to fit the model have been chosen as the final parameter
sets for the model fitting. All the parameter values and variables are positive.
2.3.3 Parameters Sensitivity and Collinearity Analysis
The sensitivity and identifiability analysis were done by the functions sensFun and collin
outlined in the R-package FME. Briefly, this is done by estimating at each data point the
derivative of the clinical score S with respect to the parameter values pj . The sensitivities
are dimensionless, as they are scaled with respect to the variables and parameter values:
Sij =
∂Sipj
∂piSi
(2.2)
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where Si corresponds to a data point and pj to a parameter. These sensitivity functions
allows us in determining which parameter is least important to the model output and
these least sensitive parameters sets can be easily fixed from the identifiability analysis
and model calibration.
Raue et al [71], distinguished between structural and practical identifiability. A struc-
tural identifiability analysis gives insight into which parameters can be simultaneously
estimated, given noise free data and a model that can fit the data perfectly. A structural
non-identifiability is caused by redundant parameterisation. Here, the structural identi-
fiability was evaluated by investigating the pairwise linear dependence or collinearity of
all possible parameters sets. If the ‘collinearity index’ calculated by the function collin
exceeds a critical values typically chosen to be 10–15, then the parameter set is regarded
as poorly identifiable [32].
In practice, all measurements have error and the model is non-perfect and this causes
the uncertainty of the parameters values characterized by confidence regions. The prac-
tical non-identifiability is characterized by an infinitely extended confidence region in
increasing and/or decreasing direction. For the estimation of confidence intervals the
data-dependent probability distribution of the parameters have to be derived. Raue et
al. introduced the profile likelihood to estimate the confidence intervals. In the present
work, a Bayesian method, in particular the Markov Chain Monte Carlo approach using
the DRAM method (Delayed Rejection Adaptive Metropolis) [72] as implemented in
FME was applied to visualize the confidence regions by pairwise scatter plots and to
estimate the confidence intervals.
2.3.4 Markov Chain Monte Carlo Algorithm
Bayesian inference provides a framework for explicitly accounting for modelling uncer-
tainties, the essential characteristics of Bayesian methods being the probability distri-
bution for describing the parameter and model uncertainty. Analysing the parameter
uncertainties by using the formal likelihood function is the heart of Bayesian inference.
Markov Chain Monte Carlo (MCMC) refers to an important class of Bayesian meth-
ods, designed to sample from a probability distributions by constructing a Markov chain
that has the desired distribution as its equilibrium distribution. MCMC is based on the
most popular mathematical property of Markov chains, as they relate to Monte Carlo
sampling and distribution estimation [73]. A Markov chain is a sequence of a random
variable for which the future state solely depends on the current state irrespective of the
events that precedes it i.e.,
p(Xn+1|Xn,Xn−1, Xn−2..., X1) = p(Xn+1|Xn).
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Markov chains can be used to generate samples of the posterior distribution of the
model parameters, using a random walk approach [74]. Many MCMC algorithms have
been developed with the aim of constructing and developing statistically more relevant
Markov chain, some of them have been explained below.
2.3.4.1 Metropolis-Hastings Algorithm
The Metropolis-Hastings (MH) algorithm is one of the simplest and most successful
MCMC method for obtaining a sequence of random samples from any probability distri-
bution for which a direct sampling would be difficult. The key idea behind this algorithm
is to randomly generate perturbations of the current state, xi, of the Markov chain and
either accept or reject the new perturbed state, xj , depending on how the probability
of the new state changes is relative to the current state. The full MH- algorithm takes
up the following form:
Suppose we have sampled the states as: xi, ..., xn.
set initial state to xi and do :
Step(1) Sample from the proposal distribution q(xj |xi)
Step(2) Evaluate α = q(xi|xj)p(xi)
q(xj |xi)p(xj)
Step(3) Accept the proposal state, xj with probability min[1, α], otherwise keep the
current state xi as the new state.
(2.3)
where Q = q(xj |xi) (simply qij) represents the proposal density, sometimes also called
as jumping distribution, posing the probability of selecting state xj while being in state
xi as well as an acceptance distribution R = (rji) with rji being the probability of ac-
cepting the state sj while being in the state si [75]. For a Metropolis algorithm, it is
essential that the proposal distribution Q is symmetric, i.e., qij = qji. Starting from a
state xi at time t, the Markov chain generates a new state xj , which totally depends
on the previous state xi, with a probability qji. This could for example be done with a
(multivariate) Gaussian function centered on the current state xi : xjiN(xi, σ2I). This
proposal is accepted as the next value if α drawn form the uniform distribution U (0,
1) satisfies:
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α <
P (xi)qji
P (xj)qij
If the new state is accepted then the procedure is repeated, proposing a new state, xj+1,
otherwise the new state is rejected and the new state will be the current state, xi.
The adaptive Metropolis (AM) algorithm is based on the classical random walk
Metropolis algorithm [76] and its modification. The key distinction of the AM algo-
rithm, from MH algorithms, is its continuous adaptation towards the target distribution
via its calculation of the covariance of the proposal distribution using the history of
chain. Keeping this characteristic intact, the proposal distribution is updated using the
information gained from the posterior distribution thus far.
An important advantage of the AM algorithms is that it starts using the accumulating
information right from the beginning of the simulation, which ensures that the search
becomes more effective even at an early stage of the simulation. To be more precise, let
us assume that at time t, the Markov chain is xi, ..., xn. The new proposal distribution
for the new state is then a Gaussian distribution with a mean at the current state xi and
covariance given by sdR, where R is the covariance matrix determined by the spatial
distribution of the states xi, ..., xn ∈ R. The scaling parameter sd depends only on the
dimension d of the vectors, to ensure reasonable acceptance rates of the proposed states.
This adaptation strategy allows the proposal distribution to reach an appropriately
scaled Gaussian approximation of target distribution, which increases the efficiency of
the simulation.
In AM, the proposal distribution is continuously adapted by setting:
Cj =
 Ci i ≤ jsd.cov(xi, ..., xn) + sdId i > j
where  > 0 is a constant value which is added on the diagonal of the covariance matrix
so as to prevent it from becoming singular and Id represents a d−dimensional identity
matrix. Initial covariance of C0, an arbitrarily positive value, according to the best prior
knowledge can be used to start the algorithm.
Delayed rejection (DR) is a way of modifying the standard MH algorithm [73], to im-
prove the efficiency of the standard algorithm. The basic idea behind DR is that, upon
rejection in a MH for the new state, xj , instead of going back to the initial state, xi, a
second new state, xj+1, is proposed which is not only depends on the initial state but
also on the rejected state. The acceptance probability of the second state is computed
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so as to retain the reversibility of the Markov chain with respect to the proposal dis-
tribution. As seen in 2.3, the acceptance probability of the new state in standard MH is :
α(xi, xj) = 1 ∧ q(xi|xj)p(xi)
q(xj |xi)p(xj)
However, in DR, upon rejection a new state xj+1 is proposed with an acceptance prob-
ability depending not only on the initial state xi but also on the state we have proposed
and rejected, xj . The second state proposal is accepted with probability:
α(xi, xj , xj+1) = 1 ∧ p(xj+1)q(xj+1, xj)q(xj+1, xj , xi)[1− α(xj+1, xj)]
p(xi)q(xi, xj)q(xi, xj , xj+1)[1− α(xi, xj)]
2.4 Microarray Data Analysis
As already explained before that I have used Illumina microarrays for analysing genome
expression data, I will now describe in brief about the algorithms utilized by Illumina
in R package lumi [77]. The basic preprocessing steps, such as the image analysis and
background correction methods, to be applied to almost all types of Illumina data, how-
ever, the methods I describe for Illumina microarray are specific to analysis of expression
data.
2.4.1 Image Processing, and Background Correction
The foreground estimation algorithm used by Illumina is a two step process described
in detail by Kuhn et al., [56]. In summary, these two steps are following:
1. All pixel intensities are altered using a sharpening transformation, which mean,
the intensity of a particular pixel is either made higher or lower if its intensity is
higher or lower in corresponds to neighbouring surrounding pixels.
2. Foreground intensities are calculated as a weighted average of signals obtained
using the four pixels nearest to each bead centre. Sharpened pixels intensities are
used in calculation and the value returned is unlogged.
Background intensities are calculated using an average of the five lowest unsharpened
pixels around each bead centre covering the area of 17×17 pixel. Background corrected
intensities are then calculated by subtracting the background estimates from the fore-
ground estimates. The function lumiB was provided by lumi for Background correction.
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2.4.2 Normalisation
The lumi package provides several normalisation options. It includes a variance-stabilising
transformation (VST) [78], that takes advantages of the technical replicates available
on every Illumina microarray. Between chip normalization was done by Variance Sta-
bilisation and Normalisation (vsn) method using LumiN function with aim that the
intensities should become independent of the mean. The vsn is used which builds upon
the facts that the variance of microarray data depends on the signal intensity and that
a transformation can be found after which the variance is approximately constant. It is
like the logarithm at the upper end of the intensity scale, approximately linear at the
lower end, and smoothly interpolates in between. The position of the cross-over point
and the slope of the linear part depends on the error distribution of the data. It also
incorporates the estimation of normalisation parameters. The vsn assumes that less
than half of the genes on the arrays are differentially transcribed across the experiment.
An advantage of vsn-transformation over log−transformation is that vsn works also on
values that are negative after background correction. The following command will do
the vsn normalisation.
Norm data = LumiN(Unnorm Data,method = ”vsn”)
2.4.3 Identification of Differential Expressed Genes (DEG’s)
The R-package Limma was used to identify the differentially expressed genes. Limma
provides functions such as topTable() and decideTests(), which summarises the results of
the linear model, perform hypothesis tests and adjust the p-values. The basic statistics
used for significance analysis id the moderated t-statistics, which is computed for each
probe and for each contrast. This has the same interpretation as an ordinary t-statistics
except that the standard errors have been moderated across genes, which means it
shrunk towards a common value, using a simple Bayesian model [79]. Moderated t-
statistics lead to p-values in the same way that ordinary t-statistics do except that
the degrees of freedom are increased, reflecting greater reliability associated with the
smoothed standard errors. A number of summary statistics are presented by topTable()
for the top genes and the selected contrast. The M-value (M) for instance is the value
of the contrast (for e.g. diseased vs control). Usually this represents a log2-fold change
between two or more experimental conditions, sometimes it represents a log2-expression
level too. The Avalues (A) is the average log2-expression level for that gene across all
the arrays and channels in the experiment. Column t is the moderated t- statistics.
Column p-value is the associated p- value after adjustment for multiple testing. The
most popular form of adjustment if fdr which is Benjamini and Hochberg’s method to
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control the false discovery rate [80]. The adjusted fdr p-value means, if all the genes
with p-value below a threshold, e.g. 0.05, are selected as differentially expressed then the
expected proportion of false discoveries in the selected group is controlled to be less than
the threshold value, in this case 5%. The B-statistics (B) is the log-odds that the gene
is differentially expressed. For example, suppose a gene X has B value of 1.5, this means
that the odds of differential expression is exp1.5, which is equals to 4.48. The probability
that the gene X is differentially expressed is ( 4.481+4.48) = 0.82, i.e., the probability is
about 82% that this gene is differentially expressed. The B- is automatically adjusted
for multiple testing by assuming that 1% of genes are expected to differentially expressed
with respect to the control.
The ebayes() function also computes one more vital statitstics. The moderated F-statistics
(F) combines the t-statistics for all the contrasts into an overall test of significance for
that gene. The F-statistic test whether any of the contrasts are non-zero for that gene,
i.e., whether that gene is differentially expressed on any contrast.
2.4.4 Cluster Analysis, and Gene Regulatory Network Modelling
Cluster analysis is a collection of statistical methods, which aims at identifying groups
of samples (in our case genes) that behaves similarly or show similar characteristics.
In general, it is also called as look-a-like groups. The easiest way is to partition the
samples using the measurement that captures similarity or distance between samples.
In this way, clusters and groups are interchangeable words. Typically, in clustering
methods, all the samples with in a cluster is considered to be equally belonging to the
cluster.
The clustering algorithms are classified into two broad categories namely, hierarchical
and non-hierarchical algorithms. In the hierarchical, one construct a hierarchy or tree
like structures of the entities involved (genes in our case). While, in non-hierarchical
method, one tends to find a position in the measurement that takes as the central place
and distance is measured from that particular central point. Identifying a right central
position is quite a challenging task and hence non-hierarchical methods are less popular
but sometimes effective when datasets contains many hundred entities. In my thesis,
I will focus on one of the non-hierarchical algorithm known as fuzzy c-mean clustering
algorithm.
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2.4.4.1 Hierarchical Clustering
Hierarchical clustering algorithms are of two types: agglomerative and divisive cluster-
ing.
Agglomerative clustering is based on the union between the two nearest clusters (or
entities). The beginning condition is realized by setting each entity as a cluster. After
a few iterations it reaches the final clusters. Basically, it is a bottom-up approach.
Whereas Divisive clustering is a top-bottom approach where one starts from one cluster
containing all the data entities. At each steps, clusters are successively split into smaller
clusters according to some dissimilarity.
Given a set of N objects, S = {S1, S2, ...SN} to be clustered and a function of distance
D(ci, cj) between two clusters or entity ci and cj , build a hierarchy tree on S : ci, cj ⊂
S, ci ∩ cj . The basic hierarchical algorithm has following steps:
1. Start by assigning each entity to a cluster, ci = si(i = 1, ...N), so that if you have
N objects, you will have N clusters ` = {c1, c2, ...cN}, each containing just one
entity.
2. Find the pair of cluster, (ci, cj) such that D(ci, cj)) ≤ D(ci′ , cj′ )∀ci′ 6= cj′ ∈ ` and
merge them into a single cluster cx = ci∪ cj . Therefore, now we have `−1 number
of new cluster, as we have merged the clusters ci, cj)intock, so that now we have
one cluster less.
3. Compute distance (similarities) between the new cluster and each of the old cluster.
4. Repeat steps 2 and 3 until all entities are clustered into a single cluster of size N .
Step 3 in the hierarchical clustering algorithms can be done in different ways, which
is what distinguishes single − linkage from complete − linkage to average − linkage
clustering. All of these differ in the definition of distance and what defines largest
distance as statistically no-distance or zero-distance. Most of the time, the distance is
based on the Euclidean distance in the sample axes. The main weakness of hierarchical
clustering methods include that they do not scale well.
2.4.4.2 Non-Hierarchical Clustering
One of the non-hierarchical clustering methods is the partitioning method. Suppose,
x as a given number of clusters as the objective and the partition of the entities to
obtain the required x clusters. In contrast to the hierarchical clustering methods, this
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partitioning method permits entities to change group membership through the cluster
formation process. The partitioning methods usually begins with an initial solution,
after which reallocation occurs according to some optimality criterion.
k-means Clustering is one of the simplest unsupervised learning algorothms that
solves the clustering problem [81]. The objective is to classify a gicen data set S =
{S1, S2, ...SN} into a certain (assume initial clusters) number of clusters. The idea is to
defive intial centroids, one for each cluster ci(i = 1, ...k). The basic steps involved in the
algorithm is as follow:
1. Initial clusters: `∗ = {c∗1, c∗2, ...c∗k}; the intial centroids should be placed as far as
possible from each other.
2. Calculate the centroids of the clusters: uij =
1
| cij |
∑
x∈cij
x, where j = 1, 2...k and i
denotes the ith iteration.
3. Take each point belonging to a give data set and associate it to the nearest centroid:
ci+1j = {x | d(x, uij ≤ d(x, uij′ ) ≤ j
′ ≤ k}
`i+1 = {ci+1j | 1 ≤ j ≤ k}
4. Repeat steps 2 and 3 until no more changes can be made to the clusters, that is,
`i+1 = `i. In other words centroids do not move any more.
Finally, this algorithm aims at minimising an objective function, in this case a squared
error function:
J =
k∑
j=1
∑
x∈cj
|| x− uj ||2
Although it can be proved that the k-means algorithm will always terminate, the al-
gorithm does not necessarily find the most optimal configuration, corresponding to the
global objective function minimum. It might get stuck in a local minimum. The algo-
rithm is also significantly sensitive to the initial randomly selected cluster centres. To
get out of the local minimum, the k-means algorithm can be run multiple times from
different initial clustering or sometime fuzzy c-means clustering technique could be used.
Fuzzy c-means (FCM is a method of clustering which allows an entity of dataset to
belong to two or more clusters with a membership value. This method was developed
by Dunn in 1973 [82] and later on improved by Bezdeck in 1981 [83]. It is frequently
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used in pattern recognition. In simple, this algorithm works by assigning membership to
each data point corresponding to each cluster center on the basis of their distance to the
cluster. Smaller the distance to the cluster center, more is its membership towards that
particular cluster center. The overall algorithm is quite similar to as that of k−means
clustering algorithm, except the following changes:
J =
N∑
i=1
k∑
j=1
µmij || x− uj ||2, 1 ≤ m <∞
where m is the Fuzzines exponent and is any real number greater than 1, N is the number
of data, k is the number of clusters, µij is the degree of membership of xi in the cluster
j.
Fuzzy partitioning is carried out by an iterative optimization of the objective function
as explained above, with the update of membership µij and the cluster centre uj by:
µij =
1
k∑
z=1
( || xi − uj ||
|| xi − uz ||
) 2
m− 1
= 1( || xi − uj ||
|| xi − u1 ||
) 2
m−1 +
( || xi − uj ||
|| xi − u2 ||
) 2
m−1 + ...+
( || xi − uj ||
|| xi − uz ||
) 2
m−1
where || xi−uj || is the distance from point i to current cluster centre j, and || xi−uz ||
is the distance from point i to other cluster centre z.
uj =
N∑
i=1
µmijxi
N∑
i=1
µmij
Iteration stops when maxij
{
| µz+1ij −µzij |
}
< , where  is a termination criterion between
0 and 1, whereas z are the iteration steps. This procedure converges to a local minimum
or a saddle point J .
The advantages of fuzzy c-means are that it gives best results for overlapped data set
and comparatively better than the k-means algorithm. Unlike k-means where data point
must exclusively belongs to one cluster center here data point is assigned membership
to each cluster center as a result of which data point may belongs to more than one
cluster center.
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2.4.4.3 Gene Regulatory Network Reconstruction
Constructing regulatory network from high throughput data is a key step in systems
biology. The Network inference was performed as previously described using the R-
package, NetGenerator tool [84–87].
Briefly, it is based on a set of linear differential equations and models the temporal
change of expression intensity of the gene xi(t) at time t as the weighted sum of all the
other n genes intensity and two external stimuli u1(t) and u2(t):
xi(t) =
n∑
j=1
wi.jxj(t) +
2∑
k=1
bi.kuk(t) for i = 1...n
The NetGenerator tool calculates the gene regulatory interaction matrix W and the
components bi,k. The parameter wi,j , which is a component of W, represents an influence
of gene j on the expression of gene i, while the parameter bi,k represents the impact of
external stimulus given by the function uk(t). The external stimuli (input perturbation)
u1(t) and u2(t) are modelled from the viral titre data for two quasi species of pIAV
strains taken from Siedel et al [2], as shown in Fig. 3.8 . A non-zero weight wi,j defines
an interaction (edge) of the inferred network where a positive weight is interpreted as
activation and a negative one represents the repression or inhibition.
2.4.4.4 Linear Regression Model for Association Between Genotype and
Phenotype
A multiple linear regression model was developed with a aim of finding an association
between the observed phenotype data, which was quantified by the symptom score S
from Manchanda et al [22], and the gene expression data. The linear regression was
performed by ”lm” function in R [88].
Chapter 3
Results
3.1 Small-scale Mathematical Model for Influenza Viruses
Quantification
3.1.1 Parameters Estimation and optimisation
Parameters estimation is one of the major challenging task in mathematical modelling.
For estimating the parameters and their uncertainties we used R package FME and
followed the procedure outlined in Soetaert et al., [69] as also explained in Method
section 2.3.2.
The parameter β was eliminated by the following model transformation: β′ = 1d−1, D′ =
D∗β, γ′ = γ∗β, δ′ = δ∗β, ω′ = ω∗β. Also, The parameters , i.e., the rate at which
inflammation gets activated, as well as ω and δ were only identified for Jena/5258 that
exhibits a biphasic course of infection. For the other three strains the kinetics of inflam-
mation is non-observable based on the measured clinical score S and the model Eqs. 2.1.
Therefore, the parameter  was set to zero and the parameter values of ω and δ were
denoted as unknown (NaN) (See Table 3.1) for the infection experiments using the virus
strains Jena/5555, Jena/2688, and Bakum/1832.
In the following text, the transformed parameters are used for better readability without
the prime. Then, the mathematical model includes 8 parameters, four of them (α, γ,
kp, ) were virus strain specific and therefore calibrated individually by fitting to the
data of the experiments with different virus strains. The two parameters δ and ω are
only relevant for biphasic course of infection and, thus, estimated only for the virus
Jena/5258. The remaining two parameters ρ and θ are host-related and, therefore, fixed,
i.e., identical for the four virus strains. For the inflammation decay we use the value
36
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Table 3.1: Model parameter values. Parameter values and their 95% confidence inter-
vals (in brackets) identified by model fit to the observed clinical scores. The parameter
values NaN denote that they could not be identified. Units of the parameters are
displayed in Table 2.1.
Parameter Infection experiments
Jena/5258 Jena/5555 Jena2688 Bakum/1832
α 3.63 3.64 2.12 2.22
[3.62, 5.78] [3.31, 4.16] [2.03, 2.29] [2.09, 2.40]
kP 3.23 5.69 3.72 4.85
[2.31, 3.29] [5.13, 6.17] [3.02, 4.54] [4.27, 5.36]
γ
′ 0.51 0.28 0.52 0.29
[0.25, 0.64] [0.28, 0.31] [0.44, 0.65] [0.24, 0.32]
θ 0.01 0.01 0.01 0.01
 6.81 0.00 0.00 0.00
δ
′ 4.27 NaN NaN NaN
ω
′ 0.13 NaN NaN NaN
ρ 1.82 1.82 1.82 1.82
1.82 d−1 published by Canini and Carrat [48]. The fixed parameter θ were calculated
by model fit to all the data sets providing a rich data set of 72 data points from four
different virus strains. The values of the fixed parameters are shown in Table 2.1 and
the remaining parameters were estimated.
First, the parameters sensitivity analysis was done to exclude any parameters to which
the model is insensitive. Then, identifiability analysis was used to determine the minimal
parameters sets for which parameters estimation is possible, given the observed data.
The parameters sensitivity and identifiability analysis methods are explained in section
2.3.3. The next step was calibration, where the Levenberg-Marquardt algorithm has been
used to fit the model, and the best fit values were estimated, using modFit function from
FME package, for a selected set of parameters. Finally, sensitivity, identifiability and
calibration methods were repeated iteratively. Fig. 3.1 displays the results of model fit
to four experimental viral infections with four different virus strains. Table 3.1 depicts
the identified values of the 8 model parameters (i.e., all but the eliminated parameter β)
together with their 95% confidence intervals (CI). Finally, a Markov Chain Monte Carlo
(MCMC) simulation was used to estimate the data dependent parameters uncertainty
and how that affects the model output.
3.1.2 Parameters Sensitivity and Identifiability
The sensitivity analysis were done by the functions sensFun outlined in the R-package
FME and also explained in the method section 2.3.3. The mean sensitivity values (aver-
aged over time) of the model parameters calculated by Eq. 2.2 for the four virus strains
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Figure 3.1: Model fit to the clinical score after infection with four different virus
strains. Top: A(H1N1)pdm09 Jena/5258; medium: A(H1N1)pdm09 Jena/5555 and
A(H1N1)pdm10 Jena/2688; bottom: European swine H1N2 Bakum/1832; all infected
with 106 TCID50 /mice; black circles: observed and averaged clinical score S; bars:
‘Std’ (standard deviation); red lines: model kinetics S as simulated using Eqs. (1)–(5);
blue dashed lines: model variable P; black dashed lines: model kinetics D ; green dotted
lines: model kinetics I.(For interpretation of the references to color in text, the reader
is referred to the web version of this article.)
are shown in Table 3.2. As displayed in Table 3.2, we used different time intervals for
averaging to exclude periods with values of S close to zero as S is in the denominator in
Eq. 2.2.
To evaluate the structural identifiability of the non-fixed parameters, the collinearity in-
dex was estimated using the function collin8 of the R-package FME. The collinearity in-
dices for all the combinations of the 8 model parameters, i.e. α, kP , γ, θ, , δ, ω, and ρ
were quite high (See Fig. 3.2) and, this, demonstrate the structural non-identifiability
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Table 3.2: Sensitivities of the model parameters. Mean value (averaged over time) of
the sensitivity with respect to the read out value S.
Parameter Infection experiments
Jena/5258 Jena/5555 Jena2688 Bakum/1832
α 2.88 0.99 1.78 1.67
kP 4.57 0.39 0.46 0.46
γ
′ 0.96 -0.12 -0.34 -0.16
θ 0.38 0.00 0.01 0.01
 0.20 0.00 0.00 0.00
δ
′ -8.03 0.00 0.00 0.00
ω
′ 0.00 0.00 0.00 0.00
ρ -0.46 0.00 0.00 0.00
of the whole parameter set. The collinearity indices for the combinations of three most
important model parameters, i.e. α, kP , and γ are shown in the Fig. 3.2b. These
values are below 5. As a rule of thumb, a collinearity index less than 10–15 estimated
by the function collin of the R-package FME is assumed to be structural identifiable [32].
(a) (b)
Figure 3.2: Collinearity indices for combinations of model parameters, (A) shows
collinearity indices value for all combination of 5 parameters, i.e., α, kP , γ, δ, and ω,
and (B) for α, kP , γ.
Fig. 3.3 show the scatter-plot matrices visualizing the model parameter values from
MCMC-generated samples, the probability distribution of the model parameters values
and their pair-wise correlation coefficients as calculated by the function pairs of the
package FME. For all four experiments the distributions of the parameters α, kP , and γ
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Figure 3.3: Scatter-plot of the Markov Chain Monte Carlo (MCMC) samples for the
virus strain Jena/5258. The top right panels show the pair-wise plot of the parameters
α, γ, ω, and kP . The range of the parameters is shown at the outer axis; 1000 random
parameter sets around the parameter set calibrated for Jena/5258. The probability
distribution for each parameter is shown in the diagonal panels. The bottom panels
give the correlation coefficients for each parameter pair.
tend to zero for both increasing as well as decreasing values and the correlation between
the parameters values is low,i.e., the highest absolute value of correlation coefficients is
0.86. That indicates, that the confidence regions are finite and these three parameters are
obviously practically identifiable based on the measured data of all the four experiments
studied. The remaining parameters are non-identifiable at all and, therefore, they were
fixed in our study. The parameter , δ, and ω were estimated as showed in Table 2.1 for
the infection with virus strain Jena/5258 that shows biphasic course. The distribution
of these parameters do not show finite borders as seen in Fig 3.3. For other three virus
strains with a monophasic course, the parameter  were set to zero and the values of
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the parameters δ and ω were irrelevant as inflammation does not cause a separate peak
in the profile of the clinical score S and, therefore, it is non-observable based on these
easily attainable experimental data.
3.1.3 Identification of important parameters for virus quantification
The model parameters kP , α, and γ were found to be the most discriminative and iden-
tifiable parameters that quantitatively characterise the four virus strains under investi-
gated in this thesis. Each of the four virus strains is characterized by a specific pattern
with respect to these three parameters as displayed on Table 3.3. For Jena/5258, the
threshold parameter δ is the most sensitive model parameter. Here, the immune defense
(D) exceeds the threshold parameter δ and triggers the onset of inflammation due to the
fact that three parameters are high: (i) α, i.e., the viral replication and infection rate,
(ii) γ, i.e. the rate of early activation of the immune system, and (iii) the parameter ,
i.e., the rate at which inflammation gets activated.
For Jena/5258, the parameter kP called maximum primary pathogenicity is the second
most sensitive parameter after the threshold parameter δ. The infection with this strain
is characterized by the highest clinical score value that is caused not by a high primary
pathogenicity kP but by the inflammation (‘secondary pathogenicity’). This parame-
ter kP has the smallest value of 3.23 for Jena/5258 and the highest value of 5.69 for
Jena/5555. The confidence intervals (CI) of kP for these two virus strains with high
temporal maximum clinical score are disjunctive, i.e., without overlap. Thus, the causes
of high clinical score in both infection courses are different: Jena/5555 causes the high
clinical score by a high primary pathogenicity, while Jena/5258 by high inflammation.
The parameter α called viral infection rate is the next most sensitive parameter for
Jena/5258 with biphasic course of infection, but the most sensitive parameter for the
other three virus strains with monophasic profile (See Table 2.2). It has the highest
identified values for the H1N1 strains Jena/5258 and Jena/5555 that are characterized
by the utmost clinical score. The CI of α for these two virus strains are disjunctive to
the respective intervals of the other two virus strains Jena/2688 and Bakum/1832.
Table 3.3: Virus-specific pattern with respect to three model parameters. Labels
‘low’ versus ‘high’ represent disjunctive confidence intervals of the respective parameter
values.
Parameter Infection experiments
Jena/5258 Jena/5555 Jena2688 Bakum/1832
α Low High Medium Medium
kP High High Low Low
γ
′ Medium Low High Low
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For all four virus strains, the parameter γ, which quantifies the rate of activation of the
immune system, is the third (fourth for Jena/5258) most sensitive parameter − after kP
and α (and after δ that is only relevant for the strain Jena/5258).
In Table 3.1, the confidence intervals are only shown for the parameters α, γ and kP .
The distribution and the pairwise scatter plot of the MCMC-generated parameter values
shown in Figs. 3.2a and 3.2b gives a hint to the practical identifiability of these three
most important model parameters.
3.2 Reconstruction of Gene Regulatory Network from Gene
Expression Data
3.2.1 Normalisation
The raw microarray data was analyzed using the “Lumi” [77] and “Limma” [89] pack-
age of the statistical language “R” [90]. Between-chip normalization was done using
VSN-transformation with “lumiN” so that the distribution of intensities should become
independent of the mean. See methods section for more details.
3.2.2 Identification of Differentially Expressed Genes (DEG’s)
One of the basic and far most interesting goals in the analysis of microarray gene ex-
pression data is the identification of differentially expressed genes (DEGs) in comparison
with the mock control. In order to control the biological and technical (experimental)
variability of the experiments, one has to make an adequate number of replicates, so
that statistical inference can have a more impact. Depending on the type of study, one
can distinguish between the cases in which one aims to study a particular cell population
or to study the disease progression. In the former case, independent replication on the
level of mRNA isolation can be obtained, whereas in the latter case, one can obtained
samples/replicated from different patients.
As in my thesis, we are working with second case, where we are looking for molecular
insights into the progression of severe influenza A virus disease, the data are given as
absolute intensities with respect to a common reference sample (i.e., mock infected). To
identify DEGs, with respect to certain biological question, one can perform a suitable
statistical test for each probes (genes). The choice of test statistics depends on the
nature of the experimental data and what biological question we are asking for. In
R-package limma, the basic statistics used for significance analysis is the moderated
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t−statistics, which is computed for each probe and for each contrast. The R-package
limma, provides topTable() as well as decideTest() functions, which summarises the
results of the linear model, perform hypothesis tests and adjust the p−value.
We used decideTest() function to estimates the differentially expressed genes through
out the whole infection process. In total, 1628 DEGs were identified during the whole
infection process (see Fig. 3.4), while the list of genes is given in the appendix table B.1.
Figure 3.4: Gene expression changes in the lungs of mice infected with influenza A
virus mp Jena/5258. A total of 1628 differentially expressed genes were identified during
the infection process of 12 days compared to controls.The new colour at each days rep-
resent unique DEGs compared to the previous days while the same old colour represent
that the presence of DEGs from the previous days, for example, dark blue represents
the DEGs presents at day 1 and continue to presents through the infection process with
different frequency while the orange colour at day 2p.i., represents new unique DEGs
present at day 2 only but not before.
Most of them, i.e. 968 genes are differentially expressed (both up- and down-regulated)
with respect to control data already at day 2 p.i. indicating a strong innate immune re-
sponse. Genes which are strongly expressed during this early phase of infection indicate
the induction of cellular factors involved in the detection of virus-associated molecular
pattern (Appendix table B.2). Some of them are known to trigger the activation of in-
nate immune response, proteins involved in antiviral response (e.g. Rsad2, Mx2, Irf7,
TLRs) and chemokine/cytokine expression (e.g. Ccl7, Cxcl1, Cxcl10) [91].
During the following two days p.i. the number of DEGs decreased markedly with less
than 400 DEGs, day 4 p.i., compared with the control. Then, a further strongly in-
creased transcriptional response was observed with 1001 DEGs at day 7 p.i.,. Genes
which are strongly expressed during this phase represent chemokine/cytokine response
(e.g. Ccl7, Cxcl− 9/− 10). Finally, during recovery a decrease of the number of DEGs
to 308 at day 12 p.i. was observed. The detailed information of genes having differential
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expression in comparison with control and for each day is provided in the Appendix
table B.1.
In order to identify candidate genes of special interest for inference of a focused small-
scale network, significantly overrepresented functional categories for 1628 DEGs were
identified using the DAVID tool [92, 93] (Appendix table B.2). A number of 20 DEGs
belong to the overrepresented GO term ”response to the virus”, with p-value of 1×10−5,
were considered. Four of them have pairwise very similar functions: Oas1a/Oas1b,
Mx1/Mx2, Ddx58/Ifih1, and H2Q7/H2Q8. Thus, 16 genes belonging to the GO
term ”response to the virus” were included in the set of genes selected for regulatory
network construction (Table 3.4).
3.2.3 Cluster Analysis
In order to group genes with similar expression patterns over the time course of infection
and to check in which extent the expression profiles of selected 20 genes are representative
for all DEGs, we performed fuzzy c-means clustering [83] using all DEGs (see Methods
2.4.4.2). The number of clusters was optimised as previously described [84]. We found
that six clusters optimally represent the dynamics in the dataset (Fig.’s 3.5a and 3.5b).
Four of the 6 clusters, i.e. the clusters 1, 4, 5 and 6 comprising 1,185 DEGs (73% of
all DEGs), are characterized by a biphasic temporal expression pattern over the time
course of infection showing strong up- and down-regulation in the early phase which is
followed by a stagnant recovery phase in the middle and further strong up- and down-
regulation in the later phase of infection, which is ultimately followed by final recovery.
Two of the four biphasic clusters, i.e. clusters 1 and 4, are being associated with the
overrepresented GO category ‘Immune response’ (See appendix table B.2)
Cluster 1 contains 375 genes that were strongly activated in the early phase of the host
response with a strong first peak at day 2 p.i. and a second peak of lower intense at day 6
p.i. and then down regulation from day 7 p.i. on. Interesting genes involved in this clus-
ter are Ifnb1, Il1a, Il1b, Myd88, Rsad2, Oas1a, Mx1, which represent the detection
of virus and activation of innate immune response by type I IFNs. The GO enrichment
analysis of genes belonging to cluster 1 shows that this cluster mainly comprised the GO
terms ‘inflammatory response’ and “response to virus”, which represents the early in-
duction of innate immune response in the host system. Cluster 4 is associated with 327
genes that were strongly activated in the later phase of the host response with a second
strong peak at day 7 p.i. and then the down regulation from day 9 p.i. on. Genes within
this cluster are e.g. Ccl−3/−4/−5, Cxcl−9/−13/−16, Stat−1/−4, Socs1, Nkfbid.
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(a)
(b)
Figure 3.5: Fuzzy c-means clustering of DEGs reveals 6 cluster, (A) Mean expres-
sion profile with standard deviation of 6 clusters, identified by fuzzy c-means cluster-
ing. The x-axis represents the days post infection whereas the y-axis represents the
mean scaled log2 fold change expression for the cluster., and (B) shows shows the
mean cluster validation index (CVI) values based on different cluster validation cri-
teria, for example Dunn index and Davis–Bouldin index (for details see [25]). The
x-axis represents the number of cluster estimated and y-axis represents the correspond-
ing CVI values. Higher value of CVI represents good estimates of the cluster num-
ber. We found 6 numbers of clusters quite stable with respect to the CVI value and
they also covers most of the expression pattern of the DEGs over infection process.
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They are assigned to the overrepresented GO terms ‘Immune response’ , ‘positive regula-
tion of immune response’, inflammatory response’, ‘response to wounding’ or ‘regulation
of cytokine production’. The cytokine and chemokine production along with their reg-
ulation by Stat and Nkfb signalling may lead to higher infiltration of immune and
inflammatory cells to the lung which may leads to acute lung injury which would be the
basis of severe pathology. Severe complications arising from highly pathogenic influenza
viruses are often associated with rapid and massive inflammatory cell infiltration. The
complex interplay between cytokines and chemokines is a key step in shaping the host’s
immune response against invading pathogens including influenza viruses. In particular,
the virus induced expression of cytokines and chemokines controls the recruitment and
activation of neutrophils, macrophages, eosinophils and further immune cells to sites of
infection. Both cluster 1 and cluster 4 are enriched with many cytokines and chemokines
genes (see Fig. 3.6a) with bipahsic behaviour, thereby posing a significant role for an
excessive host response in severe influenza infection. These data corresponds with the
mean lung histopathological score observed over time (see Fig. 3.7) [2].
Cluster 5 and cluster 6 comprise of 284 and 199 genes, respectively. Both clusters
show two strong down-regulation peaks at days 2 and 7 p.i., which allocation coincides
with temporal location of the peaks of the clusters 1 and 4. For cluster 5 the early peak is
stronger than the second one, whereas the opposite for cluster 6. These two clusters are
enriched with the GO terms ’cell projection morphogenesis’, and ‘cell morphogenesis’ ,
‘epithelium development’ respectively (Appendix table B.2). Biphasic expression profiles
of genes belonging to the clusters 1 and 4 as well as 5 and 6 indicate also a strong
expression pattern of ROS related genes. Higher expression of pro-oxidation genes such
as Ncf4 and Xdh, and down-regulation of anti-oxidation genes such as Dhdh and Cat
has been found (see Fig. 3.6b). This strong pro-oxidation stimulation may lead to acute
lung injury or pulmonary damage which further increase the severity of the disease.
Cluster 3 containing 267 genes shows up-regulation until a peak at day 9 p.i.. This
cluster is enriched with the GO terms ‘cell cycle and division’, ‘positive regulation of
T-cell, ‘lymphocytes and leukocytes activation’ and ‘positive regulation of immune sys-
tem process’, which shows strong adaptive immune response and stronger infiltration of
immune cells (See appendix table B.2).
On the contrary to the pattern of cluster 3, Cluster 2 consist of 176 genes showing
down-regulation until day 7 p.i. GO enrichment analysis reveals that genes belonging to
this cluster are associated with haemopoietic or lymphoid organ and blood vessel devel-
opment, which clearly shows that with influenza infection the developmental processes
goes down. The detailed GO enrichment analysis of all the 6 cluster is presented in
appendix table B.2.
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(a)
(b)
Figure 3.6: This figure illustrates expression profile of (A) various chemokines
and their receptors, and (B) shows higher expression of pro-oxidation genes (Ncf4
and Xdh) and lower expression of anti-oxidation genes (DhDh,Cat). The y-axis
covers the expression changes, represented as compared to the mock-infected con-
trol mice on a log2 scale, whereas the x-axis represents the days post infection.
3.2.4 Gene Regulatory Network Construction
3.2.4.1 Identification of Candidate Genes
As the number of possible networks structure increases exponentially with the number of
genes, a small number of DEGs was selected to be included in the network reconstruction
algorithm. In order to identify candidate genes of special interest for inference of a
focused small-scale network, significantly overrepresented functional categories for 1628
DEGs were identified using the DAVID tool [92, 93]. A number of 20 DEGs belonging
to the overrepresented GO term ’response to the virus’, with p-value of 1× 10−5, were
considered (See appendix table B.3). Four of them have pairwise very similar functions:
Oas1a/Oas1b, Mx1/Mx2, Ddx58/Ifih1, and H2Q7/H2Q8. Thus, the majority of
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Figure 3.7: It shows the histopathological score of lung of mice infected with In-
fluenza A virus, mp Jena/5258, as already published by Seidel et al. [2]. The x-
axis shows the progression of infection process over days, while y-axis represents the
histopathological score. Black square represents the averaged value of the histopatho-
logical score while the bars represents the standard deviation across different mice.
these 20 genes include the 16 genes assigned to the enriched GO category ’response to
virus’. In addition, we included four genes (Stat− 1/− 3, Irf1 and Socs1), which were
shown to play a crucial role in feedforward and feedback inhibition of interferon and
TLR signalling during macrophage activation [94] (Table 3.4).
Figure 3.8: The perturbation factor values were calculated from the already published
data of Seidel et al [2]. The values are calculated by the viral titre values given by Seidel
[2], multiplied by the percentage value of quasispecies mp Jena/5258 (D/G) virus. The
x-axis represents the infection process over days,(days post infection), while the y-
axis represents the scaled viral titre value of mpJena/5258 D/G quasispecies. The
blue solid line represents mpJena/5258 D222 variant while Orange solid line represents
mpJena/5258 G222 variant.
Genes Function GO Category other than 
“response to virus”
Cluster
Association
Ddx58 : Dead box 
protein
(Asp-Glu-Ala-
Asp)
1) Plays a major role in sensing viral 
infection and activation of antiviral 
responses including type-1 IFN and pro-
inflammatory cytokines. 
2) It is involved in viral double-stranded 
(ds) RNA recognition and the regulation of 
immune response.
Innate immune response.
+ve regulation of Ifn-alpha/-
beta production.
response to exogenous dsRNA.
RIG-I signalling pathway.
1
Eif2ak2: 
Eukaryotic 
Translation 
Initiation Factor 
2-Alpha Kinase
1) serine/threonine protein kinase that is 
activated by autophosphorylation after 
binding to ds-RNA.
2) Also involved in the regulation of signal 
transduction, apoptosis, cell proliferation 
and differentiation.
3) Regulates various signalling pathways 
like NF-Kappa-b, insulin-signalling 
pathway and importantly, can regulates 
various Tfs like JUN, Stat1, Stat3, Irf1, 
Atf3.
-ve regulation of viral genome 
replication.
+ve regulation of chemokine n 
cytokine regulation.
+ve regulation of NF-kappa-b 
signalling.
1
H2-Q7 or HLA-
A: MHC Class I 
Antigen A
1) Involved in the presentation of foreign 
antigens to the immune system via MHC 
class I.
Antigen processing and 
presentation.
+ve regulation of T cell 
mediated cytotoxicity.
4
Ifi27l2a: Ifi27L2 
IFN, alpha 
inducible protein 
27-like 2
1) Important paralog of this gene is IfI27, 
which mediates IFN-induced apoptosis.
Aging. 1
Ifnb1: IFN beta 1
Type 1 IFN
1) Mainly involved in the signalling of 
Toll-like receptor signalling pathway and 
Immune response IFN alpha/beta 
signalling pathway.
Adaptive immune response.
Cytokine activity.
Defense response to virus.
B-cell proliferation and 
differentiation.
1
Ifng: IFN gamma
Type 2 IFN
1) The protein encoded is a soluble 
cytokine with antiviral, immunoregulatory 
and anti-tumor properties and is a potent 
activator of macrophages.
Cytokine activity.
CD8-+ve, alpha-beta T-cell 
differentiation.
+ve regulation of IL-6, IL-12 
biosynthetic process and 
T-cell proliferation.
3
Irf1: IFN 
regulatory factor 1
1) Activator of IFN alpha and beta 
transcription and also transcription 
activators of IFN induced genes like stat1.
+ve regulation of type 1 IFN & 
IL-12.
IFN-g mediated signalling
4
Table 3.4: The 20 DEGs selected for network inference, along with their association
with different clusters.
2) Plays an important role in immune 
response directly affecting NK maturation 
and activity, macrophage production of 
IL12, Th1 development and maturation of 
CD8+ T-cells
regulation of Myd88-dependent 
TLR signalling.
CD8-+ve, alpha-beta T-cell 
differentiation.
Irf-7 1) play a role in the transcriptional 
activation of virus-inducible cellular genes, 
including Ifnb.
2) Can efficiently activate both the IFN-
beta  and the IFN-alpha genes and mediate 
their induction via both the virus-activated, 
MyD88-independent pathway and the 
TLR-activated, MyD88-dependent 
pathway.
+ve regulation of IFN- alpha/- 
beta production.
Regulation of Myd88 
dependent TLR signalling 
pathway.
1
Lcn2: Lipocalin 2 1) Iron trafficking proteins involved in 
multiple processes such as apoptosis (due 
to IL3 deprivation), innate immunity and 
renal development.
Extrinsic apoptotic signalling 
pathway.
Iron ion binding.
4
Mx1: Myxovirus 
(Influenza virus) 
resistance 1
Disease 
associated: 
Influenza virus
1) GTP metabolising proteins that 
participate in cellular antiviral response.
2) Inhibits IAV replication by decreasing or 
delaying NP synthesis and by blocking 
endocytic traffic of incoming virus 
particles.
Innate immune response.
Response to virus.
1
Myd88: Myeloid 
differentiation 
primary response 
88
1) Adapter protein involved in the Toll-like 
receptor and IL-1 receptor signalling 
pathway in the innate immune response.
2) Acts via IRAK1, IRAK2, IRF7 and 
TRAF6, leading to NF-kappa-B activation, 
cytokine secretion and the inflammatory 
response.
+ve regulation of IL-6, IL-17, 
IL-23.
+ve regulation of NF-kappa-B, 
JNK signalling.
Regulation of inflammatory 
response.
1
Oas1a n: Oas1: 
2'-5' 
Oligoadenylate 
Synthetase 1 P52 
Isoform
1) Interferon-induced, dsRNA - activated 
antiviral enzyme which plays a critical role 
in cellular innate antiviral response.
2) Mutations in this gene have been 
associated with host susceptibility to viral 
infection.
-ve regulation of viral process.
2'-5'- oligoadenylate synthetase 
activity.
1
Ptprc : Protein 
Tyrosine 
Phosphatase 
Receptor
1) PTPs are known to be signaling 
molecules that regulate a variety of cellular 
processes including cell growth, 
differentiation, mitosis, and oncogenic 
transformation.
2) Acts as a positive regulator of T-cell 
coactivation upon binding to DPP4
Activation of MAPK activity.
-ve regulation of viral genome 
replication.
-ve regulation of protein kinase 
activity.
3
Rsad2: Radical S- 1) a major role in the cell antiviral state CD4+, alpha-beta T-cell 1
Adenosyl 
Methionine 
Domain-
Containing 
Protein 2
induced by type I and type II interferon.
2) Displays antiviral activity against 
influenza A virus by inhibiting the budding 
of the virus from the plasma membrane by 
disturbing the lipid rafts.
activation and proliferation.
+ve regulation of TLR-7 and 
TLR-9 signalling pathway.
Socs1: Suppressor 
of Cytokine 
Signaling 1
1) SOCS family proteins form part of a 
classical negative feedback system that 
regulates cytokine signal transduction.
2) SOCS1 is involved in negative 
regulation of cytokines that signal through 
the JAK/STAT3 pathway.
Kinase inhibitor activity.
JAK-STAT cascade.
-ve regulation of insulin-
receptor signalling pathway
4
Stat1: Signal 
Transducer And 
Activator of 
Transcription 1
1) Involved in positive feed forward loop 
of IFN-gamma activation.
2) Acts as transcription activators and 
mediates the expression of a variety of 
genes important for cell viability in 
response to different cell stimuli and 
pathogens.
Cytokine mediated signalling 
pathway.
IFN-gamma mediated 
signalling pathway
Type-1 IFN signalling pathway.
Regulation of NF-KAPPA-B, 
JAK-STAT cascade
4
Stat3: Signal 
Transducer And 
Activator of 
Transcription 3
1) Involved in negative feedback loop for 
IFN-gamma in combination with Socs1
2) plays a key role in many cellular 
processes like cell growth and apoptosis.
Involved in JAK-STAT 
cascade.
-ve regulation of cell death &
cell proliferation
1
Tlr3: Toll like 
receptor- 3 
1) They recognize pathogen associated 
molecular patterns (PAMPs) and mediates 
the production of various cytokines.
2) It recognize dsRNA associated with 
viral infection and induces the activation of 
NF-kappa-B and production of type I 
interferons.
+ve regulation of NF-KAPPA-
B, IFN-beta, IL-6, IL-12, JNK- 
cascade.
+ve regulation of type-I and 
type-III IFNs.
+ve regulation of NF-kappa-B 
signalling.
1
Tlr7: Toll like 
receptor- 7 
1) Plays a role in pathogen recognition and 
activation of innate immunity.
2) Predominantly expressed in lung, 
placenta and spleen.
+ve regulation of IL-6, IFN-
alpha
Defense response to virus.
+ve regulation of chemokine & 
IL-8 production and IFN-
alpha/- beta synthesis
1
Tgtp1: T cell 
specific GTPase 1
1) It performs GTPase activity. Response to IFN- alpha/-
gamma.
cellular response to IFN- beta.
GTP catabolic process.
4
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For network modelling we used two input perturbation functions defined by the two
different quasispecies of mpJena/5258 calculated from the data shown by Nora [2] and
shown in Fig. 3.8.
3.2.4.2 Extraction and Integration of Prior Knowledge: Pathway Studio 9.0
Prior knowledge comprising known and possible relevant interactions was extracted from
various literature and other database sources, For example Pathway studio [95]. The
prior knowledge used for network reconstruction from the pathway studio includes only
of type direct interaction as well as expression. Several studies have shown that the
inclusion of prior knowledge improves the reliability of the network inference approach
[85–87, 96–99]. A confidence score was assigned to each prior knowledge used for the
network inference based on the source of the data. High score 0.5 was given for higher
number (≥ 70) of supporting literature references, low score 0.1 for low number (be-
tween 5 and 10) of supporting literature references and median score 0.25 for numbers
of references between 10 and 70 (See table 3.5). The prior knowledge was softly inte-
grated during the network inference i.e. flexibly. Since different data sources might be
contradictory, it is advantageous to softly integrate them during the modelling process.
3.2.4.3 Gene Regulatory Network of Murine Influenza Infection
In my thesis, I developed a system of ordinary differential equations (ODE) for con-
structing a gene regulatory network by integrating gene expression profile along with
prior knowledge, extracted from Pathway Studio 9.0 [95]. Table 3.5 shows the prior
knowledge information, and their corresponding confidence score used for network infer-
ence. As the complexity of network structure increases exponentially with the number
of genes involved, a small number of 20 DEGs were selected to be included in the net-
work reconstruction. The majority of these 20 genes include the 16 genes assigned to
the enriched GO category ”response to virus” (see Table 3.4). In addition, we included
four genes (Stat− 1/− 3, Irf1 and Socs1), which were shown to play a crucial role in
feedforward and feedback inhibition of interferon and TLR signalling during macrophage
activation [94]. Fig. 3.9 shows the flowchart for data analysis, gene selection and the
construction of regulatory network from the expression profiles of the selected genes.
The final stable regulatory network is shown in Fig. 3.10, which simulated kinetics fit
well to the expression profiles of the selected DEGs (See appendix Fig. A.1).
Overall, the network consists of two influenza variants that define the two input (per-
turbation) functions as shown in Fig. 3.8 and 37 edges, representing 27 gene-to-gene
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Table 3.5: Prior Knowledge with the corresponding confidence score
Relation Type # of References Confidence Score
Node1 Node2
1 Ifng H2−Q7 +ve 100 0.5
2 Ifng Irf1 +ve 100 0.5
3 Ifng Stat1 +ve 100 0.5
4 T lr3 Ifnb1 +ve 100 0.5
5 Ddx58 Ifnb1 +ve 74 0.5
6 Ifng Socs1 +ve 72 0.5
7 Eif2ak2 Ifnb1 +ve 11 0.25
8 Ifnb1 Eif2ak2 +ve 11 0.25
9 Ifnb1 Mx1 +ve 20 0.25
10 Ifnb1 Oas1 +ve 11 0.25
11 Ifnb1 Stat1 +ve 19 0.25
12 Ifng Myd88 +ve 14 0.25
13 Ifng Oas1 +ve 13 0.25
14 Ifng T lr3 +ve 13 0.25
15 Myd88 Ifng +ve 19 0.25
16 Myd88 Irf7 +ve 30 0.25
17 Ptprc Ifng +ve 12 0.25
18 T lr3 Ifng +ve 20 0.25
19 T lr3 Myd88 +ve 21 0.25
20 T lr7 Ifnb1 +ve 15 0.25
21 T lr7 Ifng +ve 15 0.25
22 T lr7 Myd88 +ve 23 0.25
23 T lr7 T lr3 +ve 13 0.25
24 Eif2ak2 Ifng -ve 7 0.10
25 Eif2ak2 Irf1 +ve 9 0.10
26 Ifnb1 H2−Q7 +ve 7 0.10
27 Ifnb1 Rsad2 +ve 5 0.10
28 Ifnb1 Socs1 +ve 9 0.10
29 Ifng Ddx58 +ve 10 0.10
30 Ifng Eif2ak2 +ve 9 0.10
31 Ifng Irf7 +ve 6 0.10
32 Ifng Tgtp1 +ve 7 0.10
33 Irf1 Eif2ak2 +ve 6 0.10
34 Irf1 T lr3 +ve 6 0.10
35 Myd88 Irf1 +ve 7 0.10
interactions and 10 influences of the influenza variants on the gene expression. A sub-
set of 15 of the gene-to-gene interactions (coloured green in Fig. 3.10) were previously
reported and are introduced as prior knowledge as shown in Table 3.5 extracted by
Pathway Studio [95]. The remaining 12 gene-to-gene interactions were either novel in-
teractions predicted by the inferred network or already known but not included in the
prior knowledge. Interestingly, we found among these 12 predicted edges two gene-to-
gene interactions which were previously described in literature, but not used as in prior
knowledge for the network inference: Ddx58 positively activating Stat3 and Mx1
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Figure 3.9: Flowchart showing the analysis of microarray time series data utilized
for the construction of gene regulatory networks using the NetGenerator tool [87].
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Figure 3.10: Gene-regulatory network prediction from high throughput time series
microarray data for 20 DEGs. Where ”mpJena/5258 D222” and ”mpJena/5258 G222”
represents the two influenza variants found by Seidel et al. [2]. Black edges represents
the newly predicted ones, green edges represent edges supported by the prior knowl-
edge and confirmed by the expression data-based network inference and grey dotted
edges represent prior knowledge not included in the network prediction based on the
measured gene expression profiles. The number represent the percentage of robust-
ness after 500 iteration. Arrow-head represents activation or positive regulation while
bar-head represents repression or negative regulation (that may also represent indirect
interaction).
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[100–104]. This result of validation by external data from literature confirms the pre-
dictive power of modelling. Among the 37 edges, we found 5 repressions or inhibitory
effects and 32 activations among the overall network.
3.2.4.4 Inflammatory Sub-network is Robust
As a part of the inferred network shown in Fig. 3.10, there is one positive feedback loop
formed by the interaction of the genes T lr3− Ifng − Stat1. To better understand the
regulatory mechanisms of hyper-responsive behaviour induced by severe A(H1N1)pdm09
infection, the robustness of this sub-network involving the positive feedback loop was
investigated. We constructed two differential sub-networks involving four genes (T lr3−
(a) (b)
Figure 3.11: Network inference and simulated kinetics for 4 genes, (A) Gene-
regulatory network prediction from high throughput time series microarray data by
NetGenerator 2.0 involving 4 genes which were connected to the positive feedback loop.
Where “mpJena/5258 D222” and “mpJena/5258 G222” represents the two influenza
variants found by Seidel et al. [2]. Black edges represents the newly predicted ones,
green edges represents edges supported by the prior knowledge and confirmed by the ex-
pression data-based network inference and grey dotted edges represent prior knowledge
not included in the network prediction based on the measured gene expression profiles.
The number represent the percentage of robustness after 500 iteration. Arrow-head rep-
resents activation or positive regulation while bar-head represents repression or negative
regulation (that may also represent indirect interaction). and (B) showing how well the
data was fitted to the observed gene expression data of 4 DEGs (Ifng, T lr3, Stat1, and
Eif2ak2) that are connected with the positive feedback loop as shown in result section.
Dotted line shows the observed gene expression data for a gene over a period of 12 days,
while the solid line shows the model fit. The x-axis shows the progression of infection
over days, (day post infection), while the y-axis represent the gene expression changes
(logarithmised and scaled).
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Ifng−Stat1−Eif2ak2) and 6 genes (T lr3−Ifng−Stat1−Eif2ak2−Socs1−Ifi27l2a)
adding one or three genes, respectively, that are connected via robust edges with the
3-gene-loop.
For the robustness analysis, we used the same algorithm as described above to construct
the network from the gene expression data (See Methods 2.4.4.3). The robustness anal-
ysis for the 4-gene-sub-network was performed by adding Gaussian noise of mean 0 and
standard deviation (sd) of 0.01 and repeated network inference procedure for 500 times.
The robustness analysis reveals that almost all the interactions were robust, i.e. the
edges were recovered with a rate of 90%. The final network and simulation is shown in
Fig. 3.11. The simulated profiles show good agreement with the measured gene expres-
sion data, which indicates the reliability and predictability of 4-gene-model shown in Fig.
3.11b. Similar analysis was done for the 6-gene-subnetwork with sd =0.01. The robust-
ness analysis also reveals remarkably high percentage (recovery rate ≥90%) for almost
all the interactions involved, with an exception of an edge representing the influence of
Influenza-2 variant to the gene Socs1 (62%) The final 6-gene-subnetwork and simulation
is shown in appendix Fig.’s A.2 and A.3 respectively. These results demonstrates that
the positive feedback loop formed by the genes T lr3− Ifng − Stat1 is quite stable.
3.2.4.5 High Association Between Phenotypic and Genotypic Data
To find the association between the phenotype of the disease course with the cor-
responding whole genome expression data, we used multiple linear regression mod-
elling. Here, the observed phenotypic data quantified by the clinical (symptom) score
S from Manchanda et al. [22] was used as the dependent response variable. The
scaled gene expression ratios values of the four genes of the 4-gene-subnetwork (i.e.,
Ifng, Stat1, T lr3, Eif2ak2) were used as dependent (explanatory) variables. The linear
regression model is shown in the following equation and was fit by lm function in R:
fit = lm(formula = S ≈ Ifng + Stat1 + Tlr3 + Eif2ak2− 1)
Interestingly, we found that the individual influence of the four individual independent
variables have no significance (p-values ≥ 0.3) whereas a significant influence were found
for the combined influence of the four genes on the clinical score ( overall p-value 0.024).
These results suggests that the phenotype of the disease is controlled by overall interac-
tions between independent variables rather their individual expression.
Chapter 4
Discussion
4.1 Small-scale Mathematical Models for Influenza Infec-
tion
The main focus of this study was to quantify the kinetics of influenza caused by different
viral strains based on a single model by only few most important parameters. With this
aim, a dynamic model of influenza in mice was established and fitted to experimental
data representing virus-induced clinical symptoms. Three non-fixed model parameters
were proven to be identifiable and to be suitable to quantitatively characterize the four
different virus strains under study: (i) the viral replication and infection rate (α), (ii)
the maximum primary pathogenicity (kp ), and (iii) the rate of early activation of the
immune system (γ). However, the model structure is hypothetic. Follow-up experiments,
including molecular parameters and genome-wide transcriptome analysis are ongoing to
discriminate between alternative models and to verify the hypothesis that the second
peak of biphasic course of infection is caused mainly by inflammation. Consequently,
the models suggested in the present study describe the course of influenza based on
virus infection and on virus-induced immune response, including pro- as well as an anti-
inflammatory response. Finally, they link the virus pathogenicity and/or inflammation
with the observable clinical symptoms.
The small-scale model has some interesting features: First, it can describe the outcome of
infection with four influenza virus strains. As a result, the model can be used to quantify
the virulence of different strains by a set of eight parameters listed in tables 2.1 and 3.1.
Three of them ( α, kp, γ) were found to be structurally as well as practically identifiable.
The remaining five parameters are non-identifiable with the given experimental data.
They were fixed, which no critical for four of them due to their low sensitivity (see Table
3.2). Only for the threshold parameter δ introduced by Kumar et al. [46], the practical
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non-identifiability is an issue for further studies due to its high sensitivity for biphasic
profiles of the clinical score.
The model can simulate and interpret the cause of different outcomes of disease after
virus challenge in mice. At day 2 p.i., mice became ill independently from the virus
strain and infection dose studied. Maximum clinical score was observed between days
3 and 6 after infection with Jena/5555, Bakum/1832 and Jena/2688; afterwards, mice
recovered (i.e. monophasic disease kinetic). Furthermore, there is only low or no persis-
tent inflammation. Obviously, the respective viruses have been eliminated efficiently by
the immune response. In contrast to infection with Jena/5258 virus, a biphasic course of
clinical symptoms was observed and simulated by the mathematical model. According
to the established model, persistent inflammation contributes to the biphasic course of
disease. Due to experimental design, it remains unclear whether the virus was elimi-
nated or not at the second disease phase or peak. So there is still an open question,
whether the second peak of the disease is solely due to the persistent inflammation or
due to the existence of mutant influenza virus.
For modelling of the biphasic behaviour, a dynamic model introduced and theoretically
studied by Kumar et al. [46], was used and reduced. To the best of our knowledge, in
the present work, the fist time Kumar’s model was fitted to experimental data by linking
the strength of inflammation with clinical symptoms representing influenza infection in
mice. In addition, the course of infection of A(H1N1)pdm09 virus as well as European
swine H1N2 influenza virus (Bakum/1832) was modelled the first time.
Based on the model presented here, it can be assumed that the dynamics of influenza
depends on both the virus pathogenicity as well as the adverse adaptive immune response
that includes the pro- inflammatory cytokines
The model established in the present study can interpret and quantify the biphasic
course of disease by a late inflammation phase. It allows quantifying the rate of pro-
and anti-inflammatory response ( and ρ respectively) as well as the conditions for the
onset of inflammation ( δ, ω) by a set of identified parameters. As suggested by Kumar
et al. [46], it was hypothesised with equation 2.1 that the onset of inflammation (model
variable I ) is triggered by the immune defense (if the model variable D goes beyond
the threshold value δ). The sensitivity of the pro-inflammatory response in dependence
on the immune defense is quantified by the parameter (1/ω). These results warrant a
more detailed biological characterization of pro-inflammatory response that is ongoing
now. As published recently for a non-lethal infection of C57BL/6J mice with A/Puerto
Rico/8/34 [59], a transcriptome analysis will help to clarify the role of factors of innate
and adaptive host immune response in severe biphasic influenza in mice.
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The observed clinical score was used for the presented model fit. These data are
negatively correlated with the body weight (W; Fig. 2.4). Thus, the body weight
could be used alternatively for model fit using a linear regression model as following:
(W = W0 − a ∗P− b ∗ I).
The model introduced by Canini and Carrat [48] was based on population analysis
of viral kinetics and symptom’s dynamics, which is similar to our study. The major
limitation with their model was that data of immune response were not included. Their
model was solely dependent on the pathogenicity of virus used. They assume that
natural killer cells contribute to adverse inflammation, which supports the hypothesis
of the small-scale model of the present study. In addition, the suggestion of Smith and
Perelson [36] to exploit clinical score as easily attainable experimental data supports the
approach used here.
The established model may help to quantify the dynamics of influenza induced by dif-
ferent virus strains and support the search for reasons for the severe, biphasic course of
influenza in mice. Including antiviral treatment, drug administration could be optimized
specifically for the virus strain used in further studies. The model might allow to direct
antiviral studies, including the mathematical analysis of the use of antiviral compounds
such as Oseltamivir for the treatment of pandemic influenza virus infections (as modeled
e.g., for the HIV therapy by [105]).
4.2 Reconstruction of Gene Regulatory Network from Gene
Expression Data.
Previous studies have shown that different isolates and variants of A(H1N1)pdm09 have
quite different disease kinetics, some causing severe illness and others mild [1, 2]. In
the present study, we infected BALB/c mice the once mouse-passaged A(H1N1)pdm09
isolate mpJena/5258 influenza virus causing severe, biphasic disease [2, 22]. Also, we
analysed changes in the whole genome expression over a period of 12 days to (i) de-
scribe the dynamics of host response at the molecular level as well as gene regulatory
level and (ii) to compare these patterns to the phenotypic level, in particular, to the
virus-induced symptoms (clinical score). Our analysis represents, for the first time, a
comprehensive analysis of the host response over the entire process of severe pandemic
influenza A virus infection, including both innate and adaptive immune response. The
results do not only reveal for the first-time biphasic gene expression profiles of host re-
sponse against severe pIAV infection but also correlate with the phenotype of disease,
i.e. clinical score as shown before [22]. In addition to genome expression analysis, we
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used an ordinary differential equation based modelling approach to infer a gene regu-
latory network. To our knowledge, this is the first gene regulatory network involving
two variants (HA-D222 and HA-G222 quasi-species) of A(H1N1)pdm09. The inferred
network demonstrates a positive feedback loop between Stat1, Ifng, and T lr3. This
explains the hyper-responsive behaviour of Ifng in presence of the HA-G222 variant,
shown by the interaction of this variant directly with Ifng in the regulatory network.
Recently, a high complexity for inflammatory networks, which is accompanied by high
entropy and low free energy was shown, for a highly pathogenic influenza strain (H5N1)
compared with the pandemic influenza strain (H1N1) of mild pathogenicity [23]. The
complexity of the inflammatory network may likely contribute to the severity and lethal-
ity of disease associated with the highly pathogenic influenza strain. This is in accor-
dance with our regulatory network prediction where we found a complex regulation of
Ifng (high indegree of Ifng, see Fig. 3.10). This is also shown by one study, where Ifng-
deficient Tc1- or Tc2- CD8 effector cells lead to severe impairment in lung function with
the elicitation of intense inflammatory response [106]. Furthermore, in another study
of respiratory viral infection, it has been shown that the absence of Ifng significantly
reduced the lung pathology [107].
Another recent study [108], described an elevated activation of inflammatory signalling
networks in lethal influenza infection compared with sub-lethal infection. In addition, a
positive feedback chemokine-derived loop which regulates the pro-inflammatory response
and also elevated levels of neutrophil’s infiltration was shown. This observation is in
concordance with our finding of a positive feedback loop between Ifng, Stat1 and T lr3,
where Ifng represents the pro-inflammatory gene. As pro-inflammatory cytokines lack
specific chemotactic activities, therefore, are the main factors enabling monocytes and T
lymphocytes to migrate from the peripheral blood via the vascular endothelium into the
site of inflammation/infection. Overall, our study provides strong evidence for the role of
the positive feedback loop in triggering the pro-inflammatory response in the infected site
to release immediately and to produce attractants that amplify the interstitial cellular
inflammatory response.
A latest study [2] demonstrated that HA-222D/G quasi-species of A(H1N1)pdm09 fa-
cilitates intra host evolution accompanied with severe disease. According to our regu-
latory network prediction, the HA-G222 variant, which replicates with high viral titres
in mouse trachea and lung tissues on day 6 p.i., [2], induces the strong Ifng gene ex-
pression. This may also explains the hyper-responsive behaviour of Ifng. Possibly, this
promotes the infiltration of inflammatory cells into the lung and thereby the observed
lung histopathology.
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A common feature of severe A(H1N1)pdm09 is the involvement of inflammatory immune
response, characterized by activation of epithelial cells, macrophages and the recruitment
and activation of neutrophils, eosinophils, monocytes and further immune cells. Inflam-
matory cells become activated and generate reactive oxygen species (ROS) [109]. ROS
is highly reactive and leads to lipid peroxidation and increase of tissue permeability,
which have been implicated in the pathogenesis of lung injury. The genome expres-
sion profile confirms a strong expression of pro-oxidation genes such as Ncf4 and Xdh
along with, down regulation of anti-oxidation genes such as Dhdh and Cat (Fig. 3.6b).
The strong pro-oxidation stimulation may further increase lung injury and the sever-
ity of the disease. Furthermore, studies show that, reverse mutant viruses expressing
HA and NA of the pandemic H1N1 influenza virus induced significantly higher levels of
expression of Ifng, IL1, IL6, Ccl4, Ccl5, Cxcl9, and Cxcl10 in the lungs of infected
mice [110, 111], supporting our study that the elevated pro-inflammatory response is an
important hallmark of the host’s response against pandemic influenza virus infection.
In addition, we also focused on the comparison between the virus-induced symptoms
(clinical score and body weight changes [22]) and the gene expression profile. In fact,
we have found for the first time a significant association of the virus-induced symptoms
with whole genome.
In conclusion, the intra-host evolution of HA-222D/G quasi-species of mpJena/5258
elicits a complex response in infected mouse lung, characterized by a biphasic gene
expression pattern. During the first phase, in particular, at day 2 p.i., when the HA-
D222 variant dominated in the mouse lung and trachea [2], a strong innate immune
response was detected with stronger expression of type I IFNs and pro-oxidation genes.
In the second phase of disease, the evolution of the HA-222G variant was correlated
with a hyper-responsive behaviour of Ifng via the positive feedback loop T lr3− Ifng−
Stat1. This finally leads to the stronger pro-inflammatory response demonstrated by
the second peak in the expression profiles of the majority of differentially expressed
genes at day 7 p.i. The expression profiles of the genes T lr3, Ifng, Stat1, and Eif2ak2
were biphasic like the virus-induced symptoms, shown by Manchanda et al. [2, 22].
Additional, experimental validation of this predicted network will help to explain further
its importance. The present study can serve as a significant basis for further exploring
and comparing the host response between different pandemic influenza infections and
developing control strategies.
Chapter 5
Summary
A model is a mathematical process of formulating generalised ideas of reality. The
level of information depends upon the question asked and the scale at which underly-
ing causative processes are studied. For example, in influenza infection process, most
molecular events in host-pathogen interaction, e.g. types of immune cells involved, virus
development inside the host, signalling pathways, are sometimes ignored because of the
complexity of these processes. However, many of these processes are condensed into a
single parameter in the antiviral immune defense. On the other hand, how the titres
of the virus or any other pathogen change in an individual is studied, as that is what
decides the diseased state of the host individual. Mathematical model of influenza dy-
namics helps to characterize, quantify and summarise the infection dynamics in the
murine model. By clarifying rigorously the assumptions, the variables and the param-
eters, mathematical modelling allows better understanding of infection kinetics. These
models further provide important conceptual results for e.g., replication rate, host de-
fense response. For evident ethical and practical reasons, experiments in public health
are often quite limited and impossible to perform. Thus, mathematical models appear
to be as a cheap and efficient way to explore and test hypotheses.
In my thesis, I highlighted the importance of a small-scale mathematical model for char-
acterization and quantification of different pandemic influenza A virus. By combining
the genome wide gene expression profiling with the clinical symptom score to gain in-
sights into molecular mechanism and characterization of key factors to severe influenza
infection helps to develop therapeutic measures. The biological basis for the increased
severity of some influenza viruses remains unclear. Unpredicted mutations which leads
to intra-host evolution of quasi-species, and strong inflammation are important hall-
marks of severe pandemic influenza infection. This emphasizes the need of development
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of new mathematical model describing influenza kinetics of different strains, which can
help in virus quantification based on their severity.
Apart from quantification of different influenza viruses, investigating the molecular
mechanisms of severe pandemic IAV (pdmIAV) is of great importance in controlling
the complications and reducing the pulmonary damage. In my thesis, I also performed a
comprehensive analysis of whole genome expression changes of the lung of mice infected
with the pH1N1 mpJena/5258 consisting HA-222D/G quasi-species to gain insights into
pathogenesis at the transcriptional level. I analysed gene expression data from both,
the innate and adaptive host immune response to identify key regulatory interactions
during infection. A reverse engineering approach was applied to infer a gene regulatory
network. Since the complexity of network structure increases with the number of genes,
a small number of 20 differentially expressed genes (DEGs) were selected to be included
in the network. The gene regulatory network of influenza infection shows a positive
feedback loop. The mpJena/5258 influenza virus infection is associated with biphasic
gene expression profile and a positive feedback mechanism of Ifng which correlates with
the evolution of HA-222D/G quasi-species and leads to overwhelming immune response.
Also, a significant correlation was also found between the co-expression action of three
genes (Ifng, Stat1 and Tlr3) with severity of the disease.
In conclusion, a small-scale mathematical model of pandemic H1N1(2009) influenza A
(A(H1N1)pdm09)) infection was developed with a special emphasis on the pro-inflammatory
response. Simulation analysis of this model revealed that the pro - inflammatory re-
sponse plays some adverse role on the disease condition, and it is specific to virus
strain. For the first time, the dynamics of four different influenza A virus strains (three
A(H1N1)pdm09 and one European swine H1N2) were modeled and quantified. The
established model helps us in characterising different influenza virus strains into severe
and mild categories based on few interpretable parameters. The model also shows that
the pro-inflammatory response is very specific for the virus strains and thus, it plays
a crucial role for optimisation of the therapeutic profile of drug administration that
should be designed specifically for the virus strains. Based on the model quantification,
we found that Jena/5258 was the most severe virus strain with having a biphasic clin-
ical symptom score. Moreover, to investigate the molecular mechanism behind it, we
analysed whole genome expression changes of the lung of mice infected with Jena/5258.
The intra-host evolution of HA-222D/G quasi-species of mpJena/5258 elicits a complex
response in infected mouse lung, characterized by a biphasic gene expression pattern.
During the first phase, in particular, at day 2 p.i., when the HA-D222 variant dominated
in the mouse lung, and tracheas [2], a strong innate immune response was detected with
strong expression of type I IFNs and pro-oxidation genes. In the course of second phase
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of disease, the evolution of the HA- 222G variant correlated with a hyper-responsive be-
haviour of Ifng via the positive feedback loop Tlr3 Ifng Stat1. This finally leads to the
stronger pro-inflammatory response demonstrated by the second peak in the expression
profiles of the majority of differentially expressed genes at day 7 p.i. The expression
profiles of the genes Tlr3, Ifng, Stat1, and Eif2ak2 were biphasic like the virus-induced
symptoms, shown by [2, 22]. This investigation can serve as a significant basis for fur-
ther exploring and comparing the host response between pandemic influenza infection
of different severity level and developing control strategies.
Appendix A
Appendix Figures
A.1 Simulated Kinetics for 20 Genes.
Figure A.1: It represents the output of the NetGenerator 2.0 R-package, showing
how well the data was fitted to the observed gene expression data of 20 DEGs. Dotted
line shows the observed gene expression data for a gene over a period of 12 days,
while the solid line shows the model fit. The x-axis shows the progression of infection
over days, (day post infection), while the y-axis represent the gene expression changes
(logarithmised and scaled).
66
Appendix Figures 67
A.2 Gene Regulatory Network of 6 Genes.
Figure A.2: Gene-regulatory network prediction from high throughput time series
microarray data by NetGenerator 2.0 involving 6 genes which were connected to the
positive feedback loop. “Jena/5258 HA-D222” and “Jena/5258 HA-G222” represents
the two influenza variants found by Seidel et al. [2]. Black edges represents the newly
predicted ones, green edges represents edges supported by the prior knowledge and
confirmed by the expression data-based network inference and grey dotted edges rep-
resent prior knowledge not included in the network prediction based on the measured
gene expression profiles. Arrow-head represents activation or positive regulation while
bar-head represents repression or negative regulation (that may also represent indirect
interaction).
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A.3 Simulated Kinetics for 6 Genes.
Figure A.3: Output of the NetGenerator 2.0 R-package, showing how well the data
was fitted to the observed gene expression data of 6 DEGs (Ifng, T lr3, Stat1, Eif2ak2,
Socs1, and Ifi27l2a) that are connected with the feedback loop as shown in result
section. Dotted line shows the observed gene expression data for a gene over a period
of 12 days, while the solid line shows the model fit. The x-axis shows the progression of
infection over days, (day post infection), while the y-axis represent the gene expression
changes (logarithmised and scaled).
Appendix B
Appendix Tables
The attached CD contains the following data tables used in this thesis.
B.1 Differentially Expressed Genes over days.
The file Table S1.csv contains, gene expression changes in the lungs of mice infected
with influenza A virus mp Jena/5258. A total of 1628 differentially expressed genes were
identified during the infection process of 12 days compared to controls.
B.2 Gene Enrichment for 6 Clusters.
The file Table S2.csv contains, in total, six different cluster of DEGs with similar
expression profile were identified by cluster analysis. The genes from individual clusters
were mapped to significantly overrepresented functional categories were identified using
DAVID tool.
B.3 Gene Enrichment for 1628 DEGs.
The file Table S3.csv contains, a total of 1628 differentially expressed genes were
identified during the infection process of 12 days compared to controls, were mapped to
significantly overrepresented functional categories were identified using DAVID tool.
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